maraviroc profile

ID Source	ID
PubMed CID	3002977
CHEMBL ID	256907
CHEMBL ID	1201187
CHEMBL ID	584744
CHEBI ID	63608
CHEBI ID	184662
SCHEMBL ID	51991
SCHEMBL ID	2177194
SCHEMBL ID	4576508
MeSH ID	M0493371

Synonym
AC-558
HY-13004
4,4-difluoro-cyclohexanecarboxylic acid {(s)-3-[(1s,5s)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide
4,4-difluoro-n-((s)-3-(3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-difluoro-n-((s)-3-((1s,3s,5r)-3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
bdbm50334986
4,4-difluoro-n-((1s)-3-(3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
[3h]uk 427,857
gtpl803
[3h]uk-427,857
[3h]maraviroc
gtpl806
exo-4,4-difluoro-n-[3-[3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(s)-phenylpropyl]cyclohexanecarboxamide
selzentry(tm)
celsentri(tm)
uk-427,857 maraviroc (mvc)
376348-65-1
maraviroc ,
MVC ,
uk-427857
4,4-difluoro-n-[(1s)-3-[(1r,5s)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide
uk-427,857
selzentry
celsentri
pro 140 & maraviroc
4,4-difluoro-n-[(1s)-3-[(1s,5r)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide
pro 140 (anti-ccr5 monoclonal antibody) & exo-4,4-difluoro-n-[3-[3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(s)-phenylpropyl]cyclohexanecarboxamide
DB04835
cyclohexanecarboxamide, 4,4-difluoro-n-((1s)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-
uk 427857
isopropyl, 4,4-difluoro-n-((1s)-3-{(1r,3s,5s)-3-(3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide
CHEMBL256907 ,
chebi:63608 ,
rel-maraviroc
CHEMBL1201187 ,
4,4-difluoro-n-[(1s)-3-[(1r,5s)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
CHEBI:184662
4,4-difluoro-n-[(1s)-3-[(1r,5s)-3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid
4,4-diluoro-n-[(1s)-3-[(1s,5r)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
NCGC00183109-01
NCGC00183109-02
md6p741w8a ,
maraviroc [inn:ban:jan]
unii-md6p741w8a
hsdb 8021
tox21_113369
dtxsid8048949 ,
cas-376348-65-1
dtxcid5028875
4,4-difluoro-n-[(1s)-3-{(3-exo)-3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl]cyclohexanecarboxamide
MRV ,
4,4-difluoro-n-[(1s)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide
maravirocum
4,4-difluoro-n-{(1s)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide
maraviroc [orange book]
maraviroc [who-dd]
maraviroc [mart.]
maraviroc [vandf]
maraviroc [ema epar]
maraviroc [jan]
maraviroc [mi]
cyclohexanecarboxamide, 4,4-difluoro-n-[(1s)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-
maraviroc [inn]
CS-0366
BRD-A23284911-001-02-4
SCHEMBL51991
CHEMBL584744 ,
4,4-difluoro-n-((1s)-3-((1r,5s)-3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
SCHEMBL2177194
SCHEMBL4576508
MLS006011960
smr004703532
4,4-difluoro-n-((1s)-3-((1r,5s)-3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide
AKOS025402143
J-521678
EX-A200
sr-01000942244
SR-01000942244-1
maraviroc, >=98% (hplc)
4,4-difluoro-n-[(1s)-3-[(1r,3s,5s)-3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
AKOS032946723
AKOS032960315
Q421369
4,4-difluoro-n-((s)-3-((1r,3r,5s)-3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide
AS-75265
AMY12578
cyclohexanecarboxamide,4,4-difluoro-n-[(1s)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-
bdbm50464147
EN300-22828861
2414315-81-2
gsnhkudzzfzsjb-qumgssfmsa-n
gsnhkudzzfzsjb-hlmsnrgbsa-n
A3C7SRV8DV
cyclohexanecarboxamide, 4,4-difluoro-n-[(1s)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-
maraviroc, endo-
4,4-difluoro-n-[(1s)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide
4,4-difluoro-n-[(1s)-3-[(1r,3r,5s)-3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
EN300-7367238
bdbm50583789
4,4-difluoro-n-[(1s)-3-[(1r,5s)-3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
EN300-128501
Z1614451557

Excerpt	Reference	Relevance
"Maraviroc 1 is an approved antagonist of the human CCR5 receptor which prevents the entry of HIV."	( An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2 Batchelor, DV; Corless, M; Dorr, PK; Ellis, D; Fenwick, DR; Galan, SR; Jones, RM; Mason, HJ; Middleton, DS; Perros, M; Perruccio, F; Platts, MY; Pryde, DC; Rodrigues, D; Smith, NN; Stephenson, PT; Stupple, PA; Webster, R; Westby, M; Wood, A, 2011)	1.09
"Maraviroc is an antiretroviral agent and C-C chemokine coreceptor 5 (CCR5) antagonist that is currently used to treat human immunodeficiency virus. "	( The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats. Borges, C; Cai, X; Ferris, CF; Iriah, SC; Kulkarni, PP; Madularu, D; Shalev, U, 2021)	2.42
"Maraviroc is a new antiretroviral agent that has been associated with immunomodulatory proprieties; therefore, its use may be a promising strategy to minimize the rate of rejections in HIV-infected kidney transplant (KT) recipients."	( Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients. Alfano, G; Cappelli, G; Dolci, G; Fontana, F; Franceschini, E; Guaraldi, G; Mussini, C, 2020)	1.71
"Maraviroc is an entry inhibitor of human immunodeficiency virus type 1 (HIV-1) that prevents the interaction between CCR5 and the surface subunit gp120 of the viral envelope glycoprotein (Env)."	( In vitro inhibitory effect of maraviroc on the association of the simian immunodeficiency virus envelope glycoprotein with CCR5. Affranchino, JL; Giraudy, I; González, SA; Ovejero, CA, 2021)	1.63
"Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and is the only CCR5 antagonist licensed for use as an anti-HIV-1 therapeutic. "	( Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. Borm, K; Cashin, K; Churchill, M; Duncan, R; Ellenberg, P; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Lewis, M; Roche, M; Sterjovski, J; Westby, M; Zhou, J, 2017)	2.15
"Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP)."	( Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Hodder, S; Klingman, KL; Landovitz, RJ; Manabe, YC; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Siegel, M; Stekler, JD; Swaminathan, S; Wilkin, TJ; Young, AM, 2017)	2.19
"Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5-tropic (R5) HIV-1. "	( Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Chokephaibulkit, K; Clark, A; Craig, C; Fang, A; Fourie, J; Giaquinto, C; Heera, J; Mawela, MP; McFadyen, L; Mitha, IH; Negra, MD; Valluri, SR; van der Ryst, E; Vourvahis, M; Zhang-Roper, RY, 2018)	2.19
"Maraviroc is a CCR5 antagonist used in the treatment of HIV-1 infection. "	( Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 Coronel Díaz, M; Díaz-de Santiago, A; Domínguez, E; Dronda, F; García-Bermejo, ML; Gutiérrez, C; Hernández-Novoa, B; López-Huertas, MR; Madrid-Elena, N; Moreno, S; Sastre, B; Serrano-Villar, S, 2018)	3.37
"Maraviroc (MVC) is an orally dosed CCR5 antagonist approved for use in patients infected with CCR5-trophic HIV-1."	( Towards a Maraviroc long-acting injectable nanoformulation. Clark, A; Dwyer, A; Owen, A; Rannard, SP; Savage, AC; Scott, T; Siccardi, M; Tatham, LM; Vourvahis, M, 2019)	1.64
"Maraviroc is a C-C chemokine receptor type-5 antagonist approved for the treatment of HIV-1. "	( No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects. Chan, PLS; Clark, A; Fang, A; Fate, GD; Haynes, J; Heera, J; Marshall, JC; McFadyen, L; Nedderman, A; Nepal, S; Savage, ME; Smith, KY; Valluri, SR; Vourvahis, M; Wood, LS, 2019)	2.18
"Maraviroc is a chemokine receptor 5 (CCR5) inhibitor used in the treatment of human immunodeficiency virus (HIV) that also shows therapeutic potential for several autoimmune, cancer, and inflammatory diseases that can afflict pregnant women. "	( Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. Ambrus, C; Ceckova, M; Gaborik, Z; Ptackova, Z; Sorf, A; Staud, F; Tupova, L, 2019)	2.28
"Maraviroc is a first-in-class chemokine coreceptor type-5 (CCR5) antagonist with demonstrated immunovirologic activity in treatment-experienced (TE) patients with CCR5 (R5)-tropic HIV-1; however, experience in regimens containing newer antiretroviral agents is limited. "	( Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB, 2013)	2.1
"Maraviroc (MVC) is a potent CCR5 coreceptor antagonist that is in clinical testing for daily oral pre-exposure prophylaxis (PrEP) for HIV prevention. "	( Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. Aubert, R; Aung, W; Bachman, S; García-Lerma, JG; Heneine, W; Kersh, E; Martin, A; Massud, I; Mitchell, J; Pau, CP; Solomon Tsegaye, T, 2013)	2.1
"Maraviroc is an antiretroviral drug in the CCR5 receptor antagonist class, which is used in the treatment of HIV. "	( A validated stability-indicating UPLC method for the determination of impurities in Maraviroc. Chilukuri, M; Hussainreddy, K; Narayanareddy, P; Venkataramana, M, 2014)	2.07
"Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains."	( Interactions between alcohol and the HIV entry inhibitor Maraviroc. Aweeka, FT; Beatty, GW; Gruber, VA; Lum, PJ; McCance-Katz, EF; Rainey, PM, )	1.1
"Maraviroc is a non-peptidic, low molecular weight CC chemokine receptor 5 (CCR5) ligand that has recently been marketed for the treatment of HIV infected individuals. "	( Modeling the allosteric modulation of CCR5 function by Maraviroc. Garcia-Perez, J; Kellenberger, E; Lagane, B, 2013)	2.08
"Maraviroc is a CC-chemokine receptor 5 (CCR5) antagonist with potent antiviral and cancer preventive effects. "	( Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats. Liu, FC; Tsai, YF; Yu, HP, 2013)	3.28
"Maraviroc is a CCR5 inhibitor approved in 2007 for treatment of therapy experienced adult patients infected with CCR5-tropic HIV-1 virus. "	( A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. Audino, A; Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Sciandra, M; Simiele, M, 2014)	2.08
"Maraviroc is a CCR5 antagonist that has been utilized as a viral entry inhibitor in the management of HIV-1. "	( Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Emory, JF; Marzinke, MA; Seserko, LA, 2014)	2.04
"Maraviroc is a new CCR5 antagonist designed to block HIV entry."	( CCR5 as a treatment target in pulmonary arterial hypertension. Abid, S; Adnot, S; Amsellem, V; Bobe, R; Combadière, C; Delcroix, M; Dubois-Randé, JL; Gary-Bobo, G; Gladwin, MT; Houssaini, A; Lipskaia, L; Marcos, E; Mouraret, N; Norris, KA; Parpaleix, A; Poupel, L; Quarck, R; Saker, M, 2014)	1.12
"Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. "	( Preclinical discovery and development of maraviroc for the treatment of HIV. Glisic, S; Radi, M; Tassini, S; Veljkovic, N; Veljkovic, V; Vucicevic, J, 2015)	2.13
"Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor. "	( HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. Bellecave, P; Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Marcelin, AG; Masquelier, B; Pawlotsky, JM; Recordon-Pinson, P; Rodriguez, C; Soulié, C, 2015)	2.09
"Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. "	( A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Alcami, J; Arenzana-Seisdedos, F; Azoulay, S; Cascajero, A; Colin, P; Garcia-Perez, J; Heinrich, JT; Kellenberger, E; Lagane, B; Lortat-Jacob, H; Staropoli, I, 2015)	2.1
"Maraviroc is a first-in-class selective CCR5 antagonist only approved in combination with other antiretrovirals for the treatment of HIV-infection. "	( Off-label use of maraviroc in clinical practice. Blanco, JR; Ochoa-Callejero, L, 2016)	2.22
"Maraviroc (MVC) is a potential candidate for 'on demand' preexposure prophylaxis. "	( Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. Back, D; Boix, J; Cabrera, C; Carrillo, A; Clotet, B; Coll, J; Else, L; Escrig, R; García, E; Gómez-Mora, E; Moltó, J; Ouchi, D; Paredes, R, 2015)	2.18
"The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. "	( Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R Amin, J; Andrade-Villanueva, J; Arnaiz, JA; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Fisher, M; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Sierra Madero, J; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I, 2016)	2.44
"Maraviroc is an allosteric small molecule antagonist of chemokine receptor type 5 (CCR5) and has been used in adult allogeneic hematopoietic stem cell transplant (HSCT) recipients to prevent acute graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract and liver. "	( A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Davies, SM; Fukuda, T; Kashuba, ADM; Khandelwal, P; Marsh, RA; Mehta, PA; Mizuno, K; Teusink-Cross, A; Vinks, AA, 2016)	2.13
"Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis."	( Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Klingman, KL; Landovitz, RJ; Liu, A; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, TJ; Young, AM, 2017)	2.15
"Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. "	( Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. Aiestaran, A; Artero, A; Bernal, E; Blanco, F; Flores, J; García, F; García-Deltoro, M; Gutiérrez, F; Hernández-Quero, J; Imaz, A; Martínez-Madrid, OJ; Mínguez-Gallego, C; Navarro, J; Ocampo, A; Paredes, R; Pasquau, J; Pérez, N; Pérez-Elías, MJ; Poveda, E; Ribas, MA, 2017)	2.15
"Maraviroc is a substrate for CYP3A4, and exposure will therefore be modulated by CYP3A4 inhibitors. "	( Maraviroc: in vitro assessment of drug-drug interaction potential. Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H, 2008)	3.23
"Maraviroc is a selective, reversible, small-molecule CCR5-receptor antagonist. "	( Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Bandres, JC; Fung, HB; Lieberman-Blum, SS, 2008)	3.23
"2. Maraviroc is a novel CCR5 antagonist for the treatment of HIV-1 infection."	( Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Bowers, SJ; Mitchell, RJ; Potchoiba, MJ; Schroeder, CM; Small, HF; Walker, DK, 2008)	1.12
"Maraviroc is a potent inhibitor of HIV-1 replication and contributes to effective viral suppression in combination with traditional antiretroviral medications. "	( Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection. Caldwell, DJ; Evans, JD, 2008)	1.79
"Maraviroc is a novel drug and different from the rest of the antiretrovirals due to the special characteristics of its mechanism of action and is also the first antiretroviral directed towards a cell target."	( [Introduction. A brief history of AIDS]. Alcamí, J, 2008)	1.07
"Maraviroc (MVC) is a new antagonist of the CCR5 coreceptor and is the first antiviral compound available that has a cell factor essential for HIV entry as a target. "	( [Mechanisms of resistance and failure of treatment with maraviroc]. Delgado, R, 2008)	2.03
"Maraviroc is a selective and slowly reversible antagonist of the CCR5 co-receptor which has shown to have powerful antiviral activity, in vitro, against a wide range of HIV clinical isolates, including strains multi-resistant to 4 classes of pre-existing antiretroviral drugs. "	( [At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?]. Camacho, A; Genebat, M; Leal, M; Rivero, A, 2008)	2.04
"Maraviroc is a small molecule and a member of a new class of antiretroviral compounds known as CCR5 antagonists, which block R5-tropic HIV entry into CD4 cells. "	( Maraviroc: a new CCR5 antagonist. Khanlou, H; Sayana, S, 2009)	3.24
"Maraviroc is a potent selective CCR5 antagonist and is the first of this new class of oral agents to be approved for the treatment of CCR5-tropic HIV type-1. "	( Maraviroc: pharmacokinetics and drug interactions. Abel, S; Back, DJ; Vourvahis, M, 2009)	3.24
"* Maraviroc is a CCR5 receptor antagonist, while raltegravir is a HIV-1 integrase inhibitor. "	( Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R, 2010)	1.33
"Maraviroc is an orally available antagonist of the CCR5 chemokine receptor, which acts as a human immunodeficiency virus type 1 (HIV-1) coreceptor. "	( Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations. Hirano, A; Kaneda, T; Kinoshita, E; Nomura, T; Okubo, N; Takahashi, M, 2010)	2.03
"Maraviroc is a first-in-class CCR5 antagonist that shows potent anti-HIV-1 activity in vitro and in vivo and is well tolerated in both healthy volunteers and HIV-1-infected patients. "	( An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid. Brewer, E; Clarke, P; Edgington, A; Felix, T; Muirhead, D, 2010)	2.05
"Maraviroc is a nonpeptidic small molecule human immunodeficiency virus type 1 (HIV-1) entry inhibitor that has just entered the therapeutic arsenal for the treatment of patients. "	( Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). Alcami, J; Arenzana-Seisdedos, F; Garcia-Perez, J; Kellenberger, E; Lagane, B; Rognan, D; Rueda, P, 2011)	2.14
"Maraviroc proved to be an effective antiretroviral agent for a combination therapy of HIV infection."	( [Our experience with maraviroc treatment in HIV positive patients]. Machala, L; Perlík, F; Slanar, O; Stanková, M; Vondracková, H, 2011)	1.41
"Maraviroc is a generally safe and well-tolerated medication for the treatment of HIV-1 infection with a unique mechanism of action. "	( Drug safety evaluation of maraviroc for the treatment of HIV infection. Hardy, WD; Rockstroh, JK; Wasmuth, JC, 2012)	2.12
"Maraviroc is an anti-human immunodeficiency virus drug that acts by blocking viral entry into target cells. "	( Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc. Bumpus, NN; Hendrix, CW; Lu, Y, 2012)	2.03
"Maraviroc (MVC) is a CCR5 antagonist that inhibits HIV-1 entry by binding to the coreceptor and inducing structural alterations in the extracellular loops. "	( HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. Arts, EJ; Ratcliff, AN; Shi, W, 2013)	2.16
"Maraviroc (MVC) is a drug approved for use as part of HAART in treatment-experienced HIV-1 patients with CCR5-tropic virus. "	( Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Díaz-Delfín, J; Domingo, P; Giralt, M; Villarroya, F, 2013)	3.28
"Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. "	( Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Armour, D; Dobbs, S; Dorr, P; Griffin, P; Irvine, B; Macartney, M; Mori, J; Napier, C; Perros, M; Price, D; Rickett, G; Smith-Burchnell, C; Stammen, B; Webster, R; Westby, M; Wood, A, 2005)	3.21
"Maraviroc is a CCR5 antagonist in clinical development as one of a new class of antiretrovirals targeting human immunodeficiency virus type 1 (HIV-1) coreceptor binding. "	( Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. Ciaramella, G; Dorr, P; Lewis, M; Mori, J; Mosley, M; Perros, M; Smith-Burchnell, C; Stockdale, M; Westby, M, 2007)	1.99
"Maraviroc is a specific, slowly reversible, noncompetitive, small-molecule antagonist of the CCR5 chemokine receptor, which also serves as an HIV-1 coreceptor. "	( Maraviroc. Carter, NJ; Keating, GM, 2007)	3.23
"Maraviroc (Celsentri) is an orally administered drug available as 150 and 300 mg film-coated tablets."	( [Clinical pharmacokinetic of maraviroc]. Peytavin, G, 2008)	1.36

Excerpt	Reference	Relevance
"Maraviroc has an in vitro activity against most HIV-1C viruses and could be considered as an alternative regimen in individuals infected with CCR5-tropic HIV-1C viruses."	( Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods. Aralaguppe, SG; Fekade, D; Gebre-Selassie, S; Kalu, AW; Marrone, G; Sonnerborg, A; Telele, NF, 2018)	1.51
"Maraviroc has an in vitro activity against most HIV-1C viruses and could be considered as an alternative regimen in individuals infected with CCR5-tropic HIV-1C viruses."	( Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods. Aralaguppe, SG; Fekade, D; Gebre-Selassie, S; Kalu, AW; Marrone, G; Sonnerborg, A; Telele, NF, 2018)	1.51
"Maraviroc has six impurities."	( A validated stability-indicating UPLC method for the determination of impurities in Maraviroc. Chilukuri, M; Hussainreddy, K; Narayanareddy, P; Venkataramana, M, 2014)	1.35
"Maraviroc has been proved to be effective for anti-HIV-1 by targeting CCR5."	( Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation. Bai, Q; Chen, W; Li, X; Liu, H; Yao, X; Zhang, Y, 2014)	1.35
"Maraviroc has been shown to have potent anti-inflammatory effects."	( Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock. Liu, FC; Yu, HP; Zheng, CW, 2016)	2.6
"Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials."	( A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Kuritzkes, DR; Moore, JP, 2009)	1.07
"Maraviroc has two dose formulations (150- and 300-mg tablets) and can be taken with or without food."	( Maraviroc: a new CCR5 antagonist. Khanlou, H; Sayana, S, 2009)	2.52
"Maraviroc (MVC) has shown good efficacy and tolerability in treatment-naive and treatment-experienced HIV-1-infected patients with CCR5-tropic virus. "	( Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Brudney, D; Garcia, A; Geretti, AM; Johnson, M; MacCartney, M; Marshall, N; Smith, C; Vitiello, P, 2012)	2.12
"Maraviroc (MVC) use has trailed that of other post-2006 antiretroviral therapy (ART) options for treatment-experienced patients. "	( Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients. Mugavero, MJ; Napolitano, LA; Nevin, CR; Raper, JL; Saag, MS; Tamhane, A; Wilkins, SA; Willig, JH, 2013)	3.28
"Maraviroc has no detectable in vitro cytotoxicity and is highly selective for CCR5, as confirmed against a wide range of receptors and enzymes, including the hERG ion channel (50% inhibitory concentration, >10 microM), indicating potential for an excellent clinical safety profile."	( Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Armour, D; Dobbs, S; Dorr, P; Griffin, P; Irvine, B; Macartney, M; Mori, J; Napier, C; Perros, M; Price, D; Rickett, G; Smith-Burchnell, C; Stammen, B; Webster, R; Westby, M; Wood, A, 2005)	2.49
"Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents."	( Maraviroc. Fadel, H; Temesgen, Z, 2007)	2.5
"Maraviroc has shown its clinical efficacy in patients failing other antiretroviral classes."	( [Maraviroc: clinical trials results]. Chidiac, C; Katlama, C; Yeni, P, 2008)	1.98

Excerpt	Reference	Relevance
"Maraviroc induced an increase in cell-associated HIV RNA during the administration of the drug."	( Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound. Delgado, R; Gutiérrez, C; Hernández-Novoa, B; López-Huertas, MR; Madrid-Elena, N; Moreno, S; Muñoz-Fernández, MÁ; Olalla-Sierra, J; Plana, M; Rubio, R, 2020)	1.57
"Maraviroc does not inhibit any of the major CYP450 enzymes at clinically relevant doses and it has not shown any clinically relevant effects on plasma concentrations of other agents; hence, no dose adjustments of coadministered agents are required."	( Maraviroc: pharmacokinetics and drug interactions. Abel, S; Back, DJ; Vourvahis, M, 2009)	2.52

Excerpt	Reference	Relevance
"Maraviroc treatment attenuated oxycodone-seeking in abstinent rats and reduced functional coupling in the reward circuitry. "	( The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats. Borges, C; Cai, X; Ferris, CF; Iriah, SC; Kulkarni, PP; Madularu, D; Shalev, U, 2021)	2.42
"Maraviroc treatment reduced 2B11.3-induced endocapillary hypercellularity and improved serum blood urea nitrogen levels."	( CCR2- and CCR5-mediated macrophage infiltration contributes to glomerular endocapillary hypercellularity in antibody-induced lupus nephritis. Baba, T; Ishida, Y; Kawano, M; Mukaida, N; Nagata, M; Nakatani, K; Tanabe, Y; Zoshima, T, 2022)	1.44
"Maraviroc pre-treatment (CCR5 antagonist, 40uM) blunted CCL5-induced Nox1 expression."	( CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1. Belin de Chantemele, EJ; Bruder-Nascimento, A; Bruder-Nascimento, T; Singh, S, 2022)	1.44
"Maraviroc treatment reduced tumor volume, CAF recruitment, and ERK1/2 signaling in vivo, thus, mimicking the effects observed with genetic loss of CCL5."	( Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma. Diehl, JA; Dunbar, KJ; Efe, G; Harris, M; Henick, B; Hu, J; Karakasheva, TA; Klein-Szanto, AJ; Lin, EW; Nakagawa, H; Rustgi, AK; Sachdeva, UM; Sahu, V; Tang, Q, 2023)	1.63
"Maraviroc treatment also increased apoptosis and modified cytoskeletal organization."	( CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma. Alcayaga-Miranda, F; Coletta, RD; García, C; García, IE; Godínez-Pacheco, B; González-Arriagada, WA; Lozano-Burgos, C; Maripillán, J; Martínez-Flores, R; Oyarce-Pezoa, S, 2023)	1.63
"Maraviroc treatment should not be interrupted if alcohol is consumed."	( Interactions between alcohol and the HIV entry inhibitor Maraviroc. Aweeka, FT; Beatty, GW; Gruber, VA; Lum, PJ; McCance-Katz, EF; Rainey, PM, )	1.82
"Maraviroc treatment also increased hepatic PPAR(γ) expression compared with vehicle-treated trauma-hemorrhaged rats."	( Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats. Liu, FC; Tsai, YF; Yu, HP, 2013)	2.55
"Maraviroc-treated patients had a greater increase from baseline in mean CD4(+) cell count than efavirenz-treated patients at week 240 (293 vs."	( Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S, 2014)	1.43
"Maraviroc treatment also decreased lung tissue damage as compared to the vehicle-treated trauma-hemorrhaged rats."	( Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock. Liu, FC; Yu, HP; Zheng, CW, 2016)	2.6
"Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. "	( Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H, 2010)	2.19
"Maraviroc treatment tended to result in more rapid decreases in CD38 expression on CD4(+) T cells and in plasma D-dimer concentrations than did treatment with efavirenz."	( Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H, 2010)	1.47
"Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and inflammation, although in this small study, many of the differences were not statistically significant. "	( Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H, 2010)	2.19
"Pretreatment with maraviroc (1, 2.5, 5 mg/kg, IP) reduced hyperlocomotion induced by acute cocaine (10 mg/kg) without affecting spontaneous locomotor activity."	( Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist. Cicalese, S; Nayak, SU; Oliver, CF; Rawls, SM; Tallarida, C, 2020)	0.88
"Treatment with maraviroc significantly inhibited CRC liver metastasis in the animal model."	( Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis. Adwan, H; Berger, MR; Bergmann, F; Faiza, S; Georges, R; Mahmood, S; Pervaiz, A; Zepp, M, 2021)	0.96
"Pretreatment with maraviroc blocked the effects of Tat, reinstating morphine potency in non-tolerant mice and restoring withdrawal symptomology in morphine-tolerant mice."	( CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Akbarali, HI; Dewey, WL; Gonek, M; Hauser, KF; Knapp, PE; Lippold, K; McLane, VD; Paris, JJ; Stevens, DL, 2018)	0.8
"Treatment with Maraviroc resulted in a block in S phase of LX-2 cells with increased expression levels of cyclin D1 and p21 while the expression of p53 was reduced."	( Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line. Carleo, MA; Coppola, N; De Luca, A; Esposito, V; Guerra, G; Lucariello, A; Macera, M; Martini, S; Perna, A, 2018)	1.12

Excerpt	Reference	Relevance
" Finally, the third CCR5 antagonist vicriviroc also showed long-term potent viral activity in phase II studies as long as it was boosted with low-dose ritonavir, with no significant differences in grade 3 and grade 4 adverse effects compared to placebo."	( CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. Emmelkamp, JM; Rockstroh, JK, 2007)	0.34
" There were no serious adverse events in any of these studies, and doses up to 900 mg were generally well tolerated, with postural hypotension being the dose-limiting event."	( Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Abel, S; Medhurst, CG; Muirhead, GJ; Ridgway, CE; Rosario, MC; Taylor-Worth, RJ; van der Ryst, E, 2008)	0.59
" It does not significantly influence the activity of major drug-metabolizing enzymes and is well tolerated at clinically relevant doses, with most adverse events being mild or moderate."	( Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Abel, S; Medhurst, CG; Muirhead, GJ; Ridgway, CE; Rosario, MC; Taylor-Worth, RJ; van der Ryst, E, 2008)	0.59
" Exposure-adjusted rates of adverse events were similar with maraviroc or placebo."	( Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. Fätkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, J; Mayer, H; Nelson, M; Rajicic, N, 2010)	0.87
" Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6."	( Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. Burnside, R; Craig, C; Di Perri, G; Frank, I; Goodrich, J; Heera, J; Mayer, H; McCracken, J; Pontani, D; Saag, M; Sierra-Madero, J; Wood, R, )	1.35
" It is generally well tolerated, with a similar side-effect profile to placebo in controlled studies."	( Hepatic safety and tolerability in the maraviroc clinical development program. Alston, S; Ayoub, A; Goodrich, J; Heera, J; Hoepelman, AI; Lalezari, J; Mayer, H; Mchale, M; Nelson, M; van der Ryst, E, 2010)	0.63
"Maraviroc is a generally safe and well-tolerated medication for the treatment of HIV-1 infection with a unique mechanism of action."	( Drug safety evaluation of maraviroc for the treatment of HIV infection. Hardy, WD; Rockstroh, JK; Wasmuth, JC, 2012)	2.12
" The adverse event (AE) profile was compared with the active and placebo arms of the maraviroc phase III clinical trials MOTIVATE 1 and 2, where the OBT did not include these agents."	( Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. Heera, J; Lazzarin, A; Mukwaya, G; Than, S; Valluri, SR, )	0.69
" However, data on the long-term exposure to these therapeutic options are needed, and a handful of case reports are emerging, reporting rare but potentially life-threatening adverse hepatic events in patients with hepatitis co-infection or taking other hepatotoxic drugs."	( Hepatoxicity of new antiretrovirals: a systematic review. Lacombe, K; Surgers, L, 2013)	0.39
" Adverse event (AE) and treatment-related AE incidence was 91."	( Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB, 2013)	0.66
"Maraviroc was generally safe in treatment-experienced participants for >5 years."	( Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. Burnside, R; Fatkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, JR; Mukwaya, G; Nelson, MR; Portsmouth, S, 2014)	2.13
" The frequency of serious adverse effects was investigated."	( Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E, 2014)	0.68
" Reasons for starting MVC plus DRV/r were: adverse effects in 38 individuals (63%), simplification in 15 (25%) and virological failure in seven (12%)."	( Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E, 2014)	0.68
"Most individuals starting MVC plus DRV/r qd because of simplification or adverse effects maintained HIV suppression after 48 weeks of follow-up."	( Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E, 2014)	0.68
" MVC was well tolerated with no grade 3/4 adverse events; all subjects maintained viral suppression to the end of the study."	( Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L, 2015)	0.64
" efavirenz experienced treatment-related adverse events (68."	( Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S, 2014)	0.71
"3%) adverse events (AEs) were of mild or moderate severity with few grade 3/4 events, discontinuations, or temporary discontinuations/dose reductions due to AEs or serious AEs."	( The maraviroc expanded access program - safety and efficacy data from an open-label study. Craig, C; Heera, J; Lazzarin, A; Molina, JM; Mukwaya, G; Reynes, J; Sierra-Madero, JG; Valluri, S; van der Ryst, E, )	0.69
" No subjects met protocol-defined liver stopping criteria and there were no cases of Hy's law or treatment-related hepatobiliary serious adverse events."	( Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Jagannatha, S; Mukwaya, G; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Soriano, V, )	0.34
" Safety was assessed by adverse events."	( Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. Chen, BA; Dezzutti, CS; Hendrix, CW; Hoesley, CJ; Husnik, MJ; Johnson, S; Marzinke, MA; Nel, A; Panther, L; Rabe, LK; Richardson-Harman, N; Soto-Torres, L; van der Straten, A, 2015)	0.65
"There was no difference in related genitourinary adverse events between treatment arms compared with placebo."	( Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. Chen, BA; Dezzutti, CS; Hendrix, CW; Hoesley, CJ; Husnik, MJ; Johnson, S; Marzinke, MA; Nel, A; Panther, L; Rabe, LK; Richardson-Harman, N; Soto-Torres, L; van der Straten, A, 2015)	0.65
"In this first study of a combination microbicide vaginal ring, all 4 rings were safe and well tolerated."	( Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. Chen, BA; Dezzutti, CS; Hendrix, CW; Hoesley, CJ; Husnik, MJ; Johnson, S; Marzinke, MA; Nel, A; Panther, L; Rabe, LK; Richardson-Harman, N; Soto-Torres, L; van der Straten, A, 2015)	0.65
" We recorded the ORs for dual-therapy versus control groups for serious adverse events (1·16 [0·92-1·48]), adverse events (0·82 [0·52-1·28]), and mutations (2·11 [1·32-3·36])."	( Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Achhra, AC; Amin, J; Boyd, MA; Mwasakifwa, G, 2016)	0.43
"Dual therapy, especially with regimens excluding maraviroc, could be safe and efficacious, particularly in patients with baseline viral loads of less than 100 000 copies per mL."	( Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Achhra, AC; Amin, J; Boyd, MA; Mwasakifwa, G, 2016)	0.69
" Rates of grade 3-4 adverse events did not differ among regimens (P = ."	( Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Klingman, KL; Landovitz, RJ; Liu, A; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, TJ; Young, AM, 2017)	0.71
"MVC-containing regimens were safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy."	( Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Klingman, KL; Landovitz, RJ; Liu, A; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, TJ; Young, AM, 2017)	0.71
" One (maraviroc) and two (placebo) patients experienced treatment-related hepatobiliary adverse events (AEs)."	( Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Wang, R; Zhang-Roper, R, 2017)	1.27
" Primary outcomes were grade 3 and 4 adverse events and time to permanent discontinuation of the study regimen."	( Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Hodder, S; Klingman, KL; Landovitz, RJ; Manabe, YC; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Siegel, M; Stekler, JD; Swaminathan, S; Wilkin, TJ; Young, AM, 2017)	0.75
" Grade 3 or 4 adverse events occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regimens."	( Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Hodder, S; Klingman, KL; Landovitz, RJ; Manabe, YC; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Siegel, M; Stekler, JD; Swaminathan, S; Wilkin, TJ; Young, AM, 2017)	0.75
" Safety was assessed by adverse events (AEs), colposcopy, and culture-independent analysis of the vaginal microbiome (VMB)."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
"An innovative pod-IVR delivery device with 3 different formulations delivering different regimens of ARV drugs vaginally appeared to be safe and acceptable and provided drug concentrations in CVFs and tissues exceeding concentrations achieved by highly protective oral dosing, suggesting that efficacy for vaginal HIV PrEP is achievable."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" Triple combinations resulted toxic and were rejected."	( Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells. Gutiérrez, C; Jiménez-Tormo, L; López-Huertas, MR; Luna, L; Madrid-Elena, N; Moreno, S; Vivancos, MJ, 2020)	2
" There were 25 adverse events, of which 24 were Grade 1 (G1) and one was G2 (unrelated)."	( A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). Abebe, KZ; Achilles, SL; Anton, PA; Brand, RM; Chawki, S; Chen, B; Cranston, RD; Engstrom, JC; Hendrix, CW; Jacobson, CE; Khanukova, E; Marzinke, MA; McGowan, IM; Reinhart, A; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, H; Stall, R; Steytler, J, 2022)	0.95

Excerpt	Reference	Relevance
" The integration of these models in a pharmacokinetic (PK)-pharmacodynamic (PD)-disease model can help toward a better understanding of the complexity of the interactions, as well as in the identification and clarification of the current model assumptions."	( A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Dorr, P; Hitchcock, C; Jacqmin, P; Rosario, MC; van der Ryst, E, 2005)	0.55
" An integrated pharmacokinetic-pharmacodynamic model was developed using the mixed effects modeling approach with patients' pharmacokinetic profiles on the last day of treatment, HIV-1 RNA levels over time, and the individual viral susceptibility."	( A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. Poland, B; Rosario, MC; Sullivan, J; van der Ryst, E; Westby, M, 2006)	0.56
"To assess the potential of known CYP3A4 inducers, with and without CYP3A4 inhibitors, to alter the pharmacokinetic profile of maraviroc."	( Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Abel, S; Jenkins, TM; Muirhead, GJ; Ridgway, CE; Whitlock, LA, 2008)	0.77
" No pharmacokinetic data are reported for cohort 3 because all subjects were discontinued during period 1 due to poor toleration of the drug regimen."	( Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Abel, S; Jenkins, TM; Muirhead, GJ; Ridgway, CE; Whitlock, LA, 2008)	0.57
"To assess the potential of cotrimoxazole and tenofovir, drugs which are inhibitors and/or substrates of renal transporters, to alter the pharmacokinetic profile of maraviroc."	( The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA, 2008)	0.76
" Plasma pharmacokinetic parameters from this study were compared with historical data generated in HIV-positive subjects receiving maraviroc monotherapy in a Phase IIa study."	( A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Boffito, M; Muirhead, GJ; Pozniak, AL; Ridgway, CE; Russell, D, 2008)	0.75
"To develop a population pharmacokinetic model for maraviroc, a noncompetitive CCR5 antagonist, after oral administration of tablets to healthy volunteers and asymptomatic HIV-infected subjects and to quantify the inherent variability and influence of covariates on the parameters of the model."	( A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Chan, PL; McFadyen, L; Weatherley, B, 2008)	0.86
"Rich pharmacokinetic data available from 15 studies in healthy volunteers (n = 365) and two studies in asymptomatic HIV-infected subjects (n = 48) were analysed using NONMEM."	( A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Chan, PL; McFadyen, L; Weatherley, B, 2008)	0.6
" AIMS To develop a population pharmacokinetic (PK)-pharmacodynamic (PD) model that describes CCR5 receptor occupancy by maraviroc after oral administration at different doses in healthy volunteers and HIV-positive patients and to assess the relevance of receptor occupancy in predicting the decrease in viral load (HIV-1 RNA copies ml(-1)) in HIV-positive patients."	( Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Abel, S; Dorr, P; Jacqmin, P; James, I; Jenkins, TM; Rosario, MC; van der Ryst, E, 2008)	0.78
"To model the basic pharmacokinetic (PK) characteristics of maraviroc to construct an integrated semi-mechanistic PK model for use in later population PK analyses."	( Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. McFadyen, L; Weatherley, B, 2009)	2.04
"The pharmacokinetic (PK) interaction between ritonavir-boosted elvitegravir (elvitegravir/r) and maraviroc was evaluated."	( Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. Abel, S; Hui, J; Kearney, BP; Ramanathan, S; Tweedy, S; West, S, 2010)	0.82
" Lack of PK alteration was defined as 90% confidence intervals for ratio of geometric least squares means ratio (coadministration:alone) between 70% and 143% for elvitegravir and ritonavir Cmax (maximum concentration), Ctau (trough), and AUCtau (area under plasma concentration-time curve; 0-24 hours); for maraviroc, given a 100% increase in Cmax and AUCtau (0-12 hours); the predicted 90% confidence intervals were 162% to 247% and 136% to 295%, respectively."	( Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. Abel, S; Hui, J; Kearney, BP; Ramanathan, S; Tweedy, S; West, S, 2010)	0.77
" * As both these drugs are likely to be used in combination, this study evaluated the pharmacokinetic interaction between them."	( Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R, 2010)	0.61
"To assess the two-way pharmacokinetic interaction between maraviroc and raltegravir."	( Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R, 2010)	0.85
" Test/reference ratios and 95% confidence intervals (CIs) were determined for pharmacokinetic parameters."	( Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R, 2010)	0.61
" The pharmacokinetic profile of the HIV entry inhibitor maraviroc after a single intrapartum dose in rhesus macaques was studied to determine whether maraviroc could serve as an alternative to NVP in a single-dose strategy."	( Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Holodniy, M; Kashuba, AD; Shulman, NS; Van Rompay, KK; Winters, MA, 2010)	0.84
" For the given maraviroc monotherapy sampling design, it was difficult to separate the viral dynamics system delay from a pharmacokinetic distributional delay or delay due to receptor binding and subsequent cellular signalling."	( The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. Chan, PL; Jacqmin, P; Lavielle, M; McFadyen, L; Weatherley, B, 2011)	0.92
"A pharmacokinetic study was performed in 12 HIV-negative men receiving maraviroc 300 mg twice daily for 8 days."	( Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. Brown, KC; Cohen, MS; Dumond, JB; Heidt, PE; Kashuba, AD; Malone, SA; Patterson, KB; Prince, HM; Shaheen, NJ; Spacek, MB, 2011)	0.86
"We conducted a pharmacokinetic and in vivo cerebral (1)H magnetic resonance spectroscopy ((1)H-MRS) study to assess CSF exposure and cerebral metabolite ratios (CMRs) following maraviroc intensification."	( CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. Allsop, JM; Back, D; Erlwein, OW; Garvey, L; Kaye, S; Latch, N; Mitchell, A; Nelson, M; Taylor-Robinson, SD; Watson, V; Winston, A, 2012)	0.57
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy."	( Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011)	0.37
" However, the pharmacokinetic profiles of such regimens are often not established."	( Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A, 2013)	0.65
" At steady-state (days 10 and 20), intensive pharmacokinetic sampling was undertaken."	( Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A, 2013)	0.65
"To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study."	( Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A, 2013)	0.85
"This open-label, fixed-sequence, phase 1 study evaluated the pharmacokinetic interaction between maraviroc (MVC) and ritonavir-boosted fosamprenavir (FPV/r) in healthy subjects."	( Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M, 2013)	0.88
" This study evaluated whether a pharmacokinetic interaction exists between these agents."	( Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. Ganetsky, A; Hughes, ME; Miano, TA; Porter, DL; Reshef, R; Vonderheide, RH, 2015)	0.66
"HIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12-hour pharmacokinetic profiles performed during the third trimester and ≥2 weeks after delivery."	( Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Best, B; Burchett, S; Burger, D; Capparelli, E; Colbers, A; Haberl, A; Hawkins, D; Hidalgo Tenorio, C; Kabeya, K; Kreitchmann, R; Mirochnick, M; Schalkwijk, S; Smith, E; Stek, A; Taylor, G; van Kasteren, M; Wang, J, 2015)	2.13
" Fresh and cryopreserved tissues were evaluated for human immunodeficiency virus (HIV) infection and pharmacokinetic (PK)/pharmacodynamic (PD) relationships."	( Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Chen, BA; Dezzutti, CS; Hoesley, CJ; Johnson, S; Marzinke, MA; Nel, A; Nuttall, JP; Panther, L; Richardson-Harman, N; Rohan, LC, 2016)	0.64
" The goal of this study was to establish feasibility and pharmacokinetic and pharmacodynamic profiles of maraviroc in pediatric HSCT recipients."	( A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Davies, SM; Fukuda, T; Kashuba, ADM; Khandelwal, P; Marsh, RA; Mehta, PA; Mizuno, K; Teusink-Cross, A; Vinks, AA, 2016)	0.91
" Maraviroc Cmax occurred within 4 hours in most compartments."	( Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. Back, D; Boffito, M; Dickinson, L; Egan, D; Else, L; Fox, J; Herrera, C; Jackson, A; Khoo, S; Olejniczak, N; Shattock, R; Tiraboschi, JM, 2016)	1.57
" Dose adjustment and pharmacokinetic reevaluation occurred if the average concentrations (Cavg) at Week 2 were <100 ng/mL (Stage 1-dose finding)."	( Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Chokephaibulkit, K; Clark, A; Craig, C; Fang, A; Fourie, J; Giaquinto, C; Heera, J; Mawela, MP; McFadyen, L; Mitha, IH; Negra, MD; Valluri, SR; van der Ryst, E; Vourvahis, M; Zhang-Roper, RY, 2018)	0.75
" Our results demonstrate that pharmacodynamic monitoring of CCR5 blockade unravels interpatient variability in the response to therapy and may serve as a clinically informative biomarker."	( Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Crisalli, L; Ganetsky, A; Huffman, AP; Porter, DL; Reshef, R; Richman, LP; Vonderheide, RH, 2018)	0.48
" Our results indicate that neither ABCG2 nor ABCC2 influence maraviroc pharmacokinetic but that ABCB1/Abcb1 may be partly responsible for the decreased transplacental permeability of maraviroc to the fetus."	( Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. Ambrus, C; Ceckova, M; Gaborik, Z; Ptackova, Z; Sorf, A; Staud, F; Tupova, L, 2019)	1.07
" Formal pharmacokinetic (PK) sampling was performed on days five and fifteen."	( A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects. Cameron, DW; Dennehy, M; Ghannad, M; Kanji, S; la Porte, C; Mallick, R; Sabri, E; Seguin, I; Tardiff, D; Zhang, G, 2019)	0.74
" Cohort 1 participants received two single 8 mg/kg maraviroc doses 1 week apart with pharmacokinetic sampling after each dose."	( Pharmacokinetics and safety of maraviroc in neonates. Acosta, EP; Aziz, M; Best, BM; Bradford, S; Butler, K; Chadwick, EG; Hanley, S; Hayward, K; Homans, J; Mathiba, SR; Mcfadyen, L; Mirochnick, M; Moye, J; Murtaugh, W; Reding, CA; Rosebush, JC; Samson, P; Smith, E; Vourvahis, M, 2021)	1.16
" All 13 evaluable Cohort 1 infants met the pharmacokinetic target."	( Pharmacokinetics and safety of maraviroc in neonates. Acosta, EP; Aziz, M; Best, BM; Bradford, S; Butler, K; Chadwick, EG; Hanley, S; Hayward, K; Homans, J; Mathiba, SR; Mcfadyen, L; Mirochnick, M; Moye, J; Murtaugh, W; Reding, CA; Rosebush, JC; Samson, P; Smith, E; Vourvahis, M, 2021)	0.91
"The Combination HIV Antiretroviral Rectal Microbicide-3 (CHARM-03) study was a randomized, open-label, crossover Phase 1 safety and pharmacokinetic (PK) study of oral maraviroc (MVC) and MVC 1% gel."	( A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). Abebe, KZ; Achilles, SL; Anton, PA; Brand, RM; Chawki, S; Chen, B; Cranston, RD; Engstrom, JC; Hendrix, CW; Jacobson, CE; Khanukova, E; Marzinke, MA; McGowan, IM; Reinhart, A; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, H; Stall, R; Steytler, J, 2022)	1.14
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.38
"Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.64

Excerpt	Reference	Relevance
"To characterize the cytochrome P450 enzyme(s) responsible for the N-dealkylation of maraviroc in vitro, and predict the extent of clinical drug-drug interactions (DDIs)."	( Maraviroc: in vitro assessment of drug-drug interaction potential. Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H, 2008)	2.01
" In this study we used nonhuman primates to examine the effect and mechanism of MVC alone or in combination with cyclosporine (CsA) to prolong cardiac allograft survivals."	( CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. Chen, G; Chen, W; Li, J; Stepkowski, SM; Wang, S; Xia, J; Ye, P; Zhang, K; Zhong, S, 2011)	0.37
"To evaluate the hepatic safety of maraviroc in combination with other antiretroviral agents in HIV-1-infected subjects co-infected with HCV and/or HBV."	( Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Jagannatha, S; Mukwaya, G; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Soriano, V, )	0.62
"In this 148-week randomized, double-blind, placebo-controlled, multicentre study (NCT01327547), subjects received maraviroc twice daily (n = 70) or placebo (n = 67) in combination with other antiretroviral agents."	( Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Jagannatha, S; Mukwaya, G; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Soriano, V, )	0.56
"Our preview study found that CCR5 blockade combined with cyclosporine A could attenuate the severity of liver GVHD."	( CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function. Dong, Y; Liu, H; Liu, W; Miao, S; Ren, H; Shi, Y; Tang, B; Yin, Y, 2016)	0.43
"Data showed that MVC combined with CsA reduced donor T cells migration to target organs in vivo."	( CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function. Dong, Y; Liu, H; Liu, W; Miao, S; Ren, H; Shi, Y; Tang, B; Yin, Y, 2016)	0.43
" Latently infected primary rCD4+ or central memory T cells were stimulated with MVC alone or in combination with Bryostatin-1, a PKC agonist known to reverse HIV-1 latency."	( The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Alcamí, J; Coiras, M; Gutiérrez, C; Jiménez-Tormo, L; López-Huertas, MR; Madrid-Elena, N; Moreno, S; Rodríguez-Mora, S, 2017)	0.78
"" The present studies tested the hypothesis that in evoked pain, certain chemokine receptor antagonists (CRAs), given with a submaximal dose of morphine, would result in enhanced morphine potency."	( Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management. Adler, MW; Chen, X; Cowan, A; Eisenstein, TK; Geller, EB; Inan, S; Meissler, JJ; Rawls, SM; Tallarida, CS, 2020)	0.56
" In the cold-water tail flick and formalin tests, significant increases of the antinociceptive effects of morphine were also observed when combined with CRAs."	( Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management. Adler, MW; Chen, X; Cowan, A; Eisenstein, TK; Geller, EB; Inan, S; Meissler, JJ; Rawls, SM; Tallarida, CS, 2020)	0.56

Excerpt	Reference	Relevance
" The compound was incompletely absorbed in rat (approximately 20-30%) but well absorbed in dog (>70%)."	( Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Abel, S; Comby, P; Muirhead, GJ; Nedderman, AN; Smith, DA; Walker, DK, 2005)	0.33
") maraviroc and determine the absolute bioavailability of oral maraviroc."	( Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Abel, S; Nedderman, AN; Ridgway, CE; Russell, D; Walker, DK; Whitlock, LA, 2008)	1.3
" The absolute bioavailability of 100 mg oral maraviroc is 23%."	( Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Abel, S; Nedderman, AN; Ridgway, CE; Russell, D; Walker, DK; Whitlock, LA, 2008)	0.84
"A two-compartment model parameterized to separate out absorption and clearance components on bioavailability was used."	( A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Chan, PL; McFadyen, L; Weatherley, B, 2008)	0.6
"For the typical non-Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100 mg to 33% at 600 mg."	( A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Chan, PL; McFadyen, L; Weatherley, B, 2008)	0.6
" MVC has an oral bioavailability of approximately 33%, which is limited by poor permeability as well as affinity for CYP3A and several drug transporters."	( Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. Clark, A; Owen, A; Rannard, SP; Savage, AC; Scott, T; Siccardi, M; Tatham, LM; Vourvahis, M, 2019)	0.92
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Studies in preclinical in vitro and in vivo models predicted maraviroc to have human pharmacokinetics consistent with once- or twice-daily dosing following oral administration."	( Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Armour, D; Dobbs, S; Dorr, P; Griffin, P; Irvine, B; Macartney, M; Mori, J; Napier, C; Perros, M; Price, D; Rickett, G; Smith-Burchnell, C; Stammen, B; Webster, R; Westby, M; Wood, A, 2005)	2.01
"To use a viral dynamics model to compare the effectiveness of in vivo viral inhibition of several doses of maraviroc (MVC;UK-427,857) and to use a modeling approach to support design decisions for a monotherapy study using various dosing regimens of maraviroc given with and without food."	( A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. Poland, B; Rosario, MC; Sullivan, J; van der Ryst, E; Westby, M, 2006)	0.77
" The mean total recovery of dosed radioactivity was 96%, with the majority of radioactivity being recovered within 96 h postdose."	( Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Abel, S; Nedderman, AN; Ridgway, CE; Russell, D; Walker, DK; Whitlock, LA, 2008)	0.58
" The current approved daily dosage of maraviroc is 300 mg bid in combination with other antiretroviral medications."	( [Clinical pharmacokinetic of maraviroc]. Peytavin, G, 2008)	0.91
" From a practical point of view, standardised tests are currently unavailable to assess susceptibility to MVC, although in dose-response phenotype tests a maximum percentage inhibition (MPI) < 95% would be indicative of resistance to the compound."	( [Mechanisms of resistance and failure of treatment with maraviroc]. Delgado, R, 2008)	0.59
"The mechanism of action, pharmacology, pharmacokinetics, clinical efficacy, drug interactions, adverse effects, dosage and administration, cost, and role in therapy of maraviroc are reviewed."	( Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Pasquale, TR; Sahloff, EG; Yost, R, 2009)	1.99
"In this exploratory study involving extensively treatment-experienced patients with advanced, non-R5 HIV-1 infection, neither superiority nor noninferiority was statistically demonstrated for either maraviroc dosage compared with placebo at 24 weeks of treatment."	( A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. Clotet, B; Clumeck, N; Fätkenheuer, G; Goodrich, J; Mayer, H; Saag, M; Sullivan, J; van der Ryst, E; Westby, M, 2009)	0.8
" The dosing recommendations are based on concomitant medications due to drug interactions."	( Maraviroc: a new CCR5 antagonist. Khanlou, H; Sayana, S, 2009)	1.8
" Secondly, a sigmoid E(max)vs dose model of dose-normalized non-compartmental AUC from oral dosing in 134 healthy young males and females across five phase 1 studies was constructed."	( Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. McFadyen, L; Weatherley, B, 2009)	1.8
" Providers should be aware of the need for tropism determination and dosing requirements for maraviroc."	( Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. McKinnell, JA; Saag, MS, 2009)	0.57
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Minor, clinically nonsignificant effects on the pharmacokinetics of raltegravir coadministered with lersivirine were observed at steady state for raltegravir, with estimated mean changes of -15%, -29%, and +25% in the area under the concentration-time profile from time zero to the end of the dosing interval (AUC(tau)), maximum plasma concentration (C(max)), and concentration observed 12 h postdose (C(12)), respectively."	( Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Banerjee, S; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012)	0.61
"To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir."	( Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J, 2012)	1.04
" The 50% inhibitory concentration (IC(50)), 90% inhibitory concentration (IC(90)) and dose-response curve slopes were determined for each drug."	( Baseline susceptibility of primary HIV-2 to entry inhibitors. Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N, 2012)	0.38
"Current product labels for maraviroc and raltegravir provide no dosing guidance for patients with end-stage liver disease and worsening renal function."	( Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma. Boyd, SD; McLaughlin, M; Morse, CG; Pau, AK; Penzak, SR, 2012)	1.09
" This is apparently due to MVC's twice-daily dosing schedule."	( CCR5 inhibitors: emergence, success, and challenges. Das, D; Maeda, K; Mitsuya, H; Nakata, H, 2012)	0.38
" The use of SF and PK-PD disease models can be a valuable tool to predict dose-response of NMEs and support rational dose selection for monotherapy trials."	( From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. Fang, J; Jadhav, PR, 2012)	0.38
" MVC was added to cART for 24 weeks, at the recommended dosage per drug-drug interactions."	( Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. Allavena, C; Barbuat, C; Corbeau, P; Cuzin, L; Delobel, P; Flandre, P; Ghosn, J; Lascoux-Combe, C; Peytavin, G; Psomas, C; Reynes, J; Trabelsi, S, 2012)	1.82
" MVC dosing was informed by the pharmacokinetic profile seen in blood and rectal tissues and consisted of a human-equivalent dose given 24 h before virus exposure, followed by a booster postexposure dose."	( Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. Aubert, R; Aung, W; Bachman, S; García-Lerma, JG; Heneine, W; Kersh, E; Martin, A; Massud, I; Mitchell, J; Pau, CP; Solomon Tsegaye, T, 2013)	0.66
"With SQV/r, geometric mean steady-state maraviroc area under the plasma concentration-time curve for the dosing interval (AUCtau) was 5,341 (coefficient of variation [CV], 27%), 8,119 (35%), and 6,193 (27%) h•ng/mL, in normal function, mild, and moderate impairment groups, respectively."	( Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. Checchio, T; Fang, J; Heera, J; McFadyen, L; Milton, A; Vourvahis, M; Weatherley, B, )	0.66
"The data suggest that no dosing interval adjustments are required in subjects with renal impairment when maraviroc is administered alone."	( Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. Checchio, T; Fang, J; Heera, J; McFadyen, L; Milton, A; Vourvahis, M; Weatherley, B, )	0.6
" Pharmacokinetic parameters, assessed on day 5 of period 1 and on days 10 and 20 of period 2, included the maximum plasma concentration (Cmax), the concentration at end of dosing interval (Cτ), and the area under the curve over dosing interval (AUCτ)."	( Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M, 2013)	0.66
"MVC exposures were significantly increased with BOC or TVR, therefore MVC should be dosed at 150 mg twice daily when coadministered with these newly approved hepatitis C protease inhibitors."	( The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. Fang, A; Heera, J; Kantaridis, C; Plotka, A; Vourvahis, M, 2014)	0.64
"Despite improvements in access to antiretroviral therapy and the use of simplified dosing regimens, HIV infection is still an important global public health problem."	( An overview of antiretroviral pre-exposure prophylaxis of HIV infection. McGowan, I, 2014)	0.4
" While solid dosage forms like films and tablets increase retention, they often require more than 15 min to fully dissolve, potentially increasing the risk of inducing epithelial abrasions during sex."	( Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Ball, C; Woodrow, KA, 2014)	0.68
" This modelling technique is able to inform the design of clinical studies, and allows assessment of pragmatic dosing strategies under complex therapeutic scenarios."	( Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. Back, D; Davies, G; Khoo, S; Owen, A; Schipani, A; Siccardi, M, 2015)	0.63
" These results provide a framework for future early investigations of antiretroviral efficacy in HIV prevention to optimize dosing strategies in clinical investigations."	( Models for predicting effective HIV chemoprevention in women. Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C, 2015)	0.42
"The potential of maraviroc (MVC), a small-molecule CCR5 antagonist, as a candidate to prevent HIV-1 sexual transmission by oral or topical dosing has not yet been completely established."	( Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. Armanasco, N; Fletcher, P; Herrera, C; Nuttall, J; Shattock, RJ, 2016)	1.02
" Using an in vitro model of Ebola Zaire replication with transcription-competent virus like particles (trVLPs), requiring only level 2 biosafety containment, we compared the activities of the type I interferons (IFNs) IFN-α and IFN-ß, a panel of viral polymerase inhibitors (lamivudine (3TC), zidovudine (AZT) tenofovir (TFV), favipiravir (FPV), the active metabolite of brincidofovir, cidofovir (CDF)), and the estrogen receptor modulator, toremifene (TOR), in inhibiting viral replication in dose-response and time course studies."	( A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. Baker, DP; Branch, DR; Fish, EN; Hoenen, T; Kobinger, GP; Kozlowski, HN; Majchrzak-Kita, B; McCarthy, SD; Racine, T, 2016)	0.43
" A significant research thrust in the field has been to characterize different dosage forms for formulation of physicochemically diverse antiretroviral drugs."	( Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application. Golan-Paz, S; Jiang, Y; Ramanathan, R; Read, B; Woodrow, KA, 2016)	0.43
" New drugs that offer new mechanisms of action, improvements in potency and activity even against multidrug-resistant viruses, dosing convenience, and tolerability have been approved."	( [Companion Diagnostics for Selecting Antiretroviral Drugs against HIV-1]. Fukutake, K, 2015)	0.42
" Data were log-transformed and analyzed by linear least squared regression, nonlinear Emax dose-response model and Satterthwaite t test."	( Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Chen, BA; Dezzutti, CS; Hoesley, CJ; Johnson, S; Marzinke, MA; Nel, A; Nuttall, JP; Panther, L; Richardson-Harman, N; Rohan, LC, 2016)	0.64
" The CCR5-antagonist maraviroc (MVC), the non-nucleoside reverse transcriptase inhibitors (NNRTIs) etravirine (ETV) and rilpivirine (RPV), as well as the integrase strand transfer inhibitor (INSTI) raltegravir (RAL), have all been evaluated using both oral and non-oral dosing regimens, demonstrating a need for dynamic and sensitive bioanalytical tools for drug quantification in plasma and tissue."	( Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue. Marzinke, MA; Parsons, TL, 2016)	0.96
" One-hundred and three participants were enrolled into 4 age/formulation cohorts and dosed twice daily."	( Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Chokephaibulkit, K; Clark, A; Craig, C; Fang, A; Fourie, J; Giaquinto, C; Heera, J; Mawela, MP; McFadyen, L; Mitha, IH; Negra, MD; Valluri, SR; van der Ryst, E; Vourvahis, M; Zhang-Roper, RY, 2018)	0.75
"The maraviroc dosing strategy resulted in participants achieving the target Cavg, with exposure ranges similar to those observed in adults on approved doses."	( Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Chokephaibulkit, K; Clark, A; Craig, C; Fang, A; Fourie, J; Giaquinto, C; Heera, J; Mawela, MP; McFadyen, L; Mitha, IH; Negra, MD; Valluri, SR; van der Ryst, E; Vourvahis, M; Zhang-Roper, RY, 2018)	1.3
" All patients completed full maraviroc dosing and follow-up."	( Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 Coronel Díaz, M; Díaz-de Santiago, A; Domínguez, E; Dronda, F; García-Bermejo, ML; Gutiérrez, C; Hernández-Novoa, B; López-Huertas, MR; Madrid-Elena, N; Moreno, S; Sastre, B; Serrano-Villar, S, 2018)	2.21
" Maraviroc (MVC) is an orally dosed CCR5 antagonist approved for use in patients infected with CCR5-trophic HIV-1."	( Towards a Maraviroc long-acting injectable nanoformulation. Clark, A; Dwyer, A; Owen, A; Rannard, SP; Savage, AC; Scott, T; Siccardi, M; Tatham, LM; Vourvahis, M, 2019)	1.83
"Intravaginal rings (IVRs) for HIV pre-exposure prophylaxis (PrEP) theoretically overcome some adherence concerns associated with frequent dosing that can occur with oral or vaginal film/gel regimens."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs."	( Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR, 2019)	0.51
" Non-standard maraviroc use also comprised reported once daily dosing (20."	( Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. Boucher, C; De Luca, A; Döring, M; Geretti, AM; Incardona, F; Kaiser, R; Lengauer, T; Pezzotti, P; Pfeifer, N; Schülter, E; Vandamme, AM; Zazzi, M, 2019)	1.14
" However, dosing is usually two times per day, unlike most currently recommended antiretroviral therapies."	( Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT Abramowicz, I; Bradshaw, D; Bremner, S; Gilleece, Y; Perry, N; Verma, S, 2020)	0.74
" At a single site, healthy HIV-uninfected men and women were enrolled and randomized to an open label crossover sequence of eight consecutive daily exposures to MVC 300 mg dosed orally, MCV 1% gel dosed rectally, and MVC 1% gel dosed vaginally."	( A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). Abebe, KZ; Achilles, SL; Anton, PA; Brand, RM; Chawki, S; Chen, B; Cranston, RD; Engstrom, JC; Hendrix, CW; Jacobson, CE; Khanukova, E; Marzinke, MA; McGowan, IM; Reinhart, A; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, H; Stall, R; Steytler, J, 2022)	0.95
" Application of maraviroc with morphine can reduce effective dosage of morphine 2,3 fold."	( [Potential application of maraviroc in the therapy of neuropathic pain]. Olakowska, E; Sojka, P; Właszczuk, A, 2021)	1.27
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.38
" The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.16
" Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.16
"While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	2.64
" An MSI threshold for classifying daily adherence was established using clinical samples from healthy volunteers following directly observed dosing of 1 to 7 doses MVC/week."	( Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305. Amico, KR; Gandhi, M; Gerona, RR; Gilliland, WM; Gulick, RM; Kashuba, ADM; Mayer, KH; Rosen, EP; White, N, 2023)	1.16
" Dosing followed recommendations for HIV therapy in the Summary of Product Characteristics for maraviroc."	( Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. Abramowicz, I; Bradshaw, D; Bremner, S; Chadwick, D; Clarke, E; Curnock, M; Fox, A; Gilleece, Y; Gompels, M; Housman, R; Jennings, L; Kirk, S; Lambert, P; Miras, H; Nelson, M; Orkin, C; Perry, N; Robinson, R; Verma, S, 2023)	1.36

Class	Description
tropane alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	32.4797	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	22.5978	0.0002	29.3054	16,493.5996	AID743069; AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	255.0000	0.4000	3.1000	9.7000	AID721751
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	110.0000	0.1100	7.1903	10.0000	AID1473738
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0001	1.7740	10.0000	AID1897799
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	9.0000	0.0001	1.7536	10.0000	AID1897803; AID1897804
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0000	2.0151	10.0000	AID1897802
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	14.4000	0.0000	2.8005	10.0000	AID1897800
Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)	IC50 (µMol)	63.0957	0.1200	4.0480	10.0000	AID1207375
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0000	2.3983	10.0000	AID1897801
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0014	0.0003	0.3887	7.0000	AID465010
C-C chemokine receptor type 5	Homo sapiens (human)	IC50 (µMol)	0.0044	0.0002	0.2567	9.0000	AID1062970; AID1065004; AID1065005; AID1065006; AID1065007; AID1121816; AID1191659; AID1370975; AID1400606; AID1713967; AID1808908; AID1820204; AID1897751; AID393050; AID395483; AID465010; AID479402; AID554132; AID707904
C-C chemokine receptor type 5	Mus musculus (house mouse)	IC50 (µMol)	0.0052	0.0003	0.0017	0.0052	AID1353545
Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)	IC50 (µMol)	63.0957	0.1200	4.0480	10.0000	AID1207375
C-C chemokine receptor type 5	Macaca mulatta (Rhesus monkey)	Ki	0.0002	0.0002	0.0002	0.0002	AID1121818; AID1713968
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	81.7122	0.0009	1.9014	10.0000	AID1207469; AID1207499; AID1207529
Sodium channel protein type 5 subunit alpha	Homo sapiens (human)	IC50 (µMol)	815.4785	0.0003	3.6484	9.2000	AID1207315; AID1207345
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	297.0000	0.1600	3.9571	8.6000	AID721752
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	17.3000	0.0100	2.7656	10.0000	AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
C-C chemokine receptor type 5	Homo sapiens (human)	EC50 (µMol)	0.0180	0.0070	2.0936	5.0119	AID1820206
C-C chemokine receptor type 5	Homo sapiens (human)	Kd	0.0250	0.0030	0.0140	0.0250	AID652438
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
C-C chemokine receptor type 5	Homo sapiens (human)	IC90 (µMol)	0.0100	0.0100	0.0100	0.0100	AID249028
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
epithelial cell maturation	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
male gonad development	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
vestibular nucleus development	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
secretory granule organization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to cAMP	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to acidic pH	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to light stimulus	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cardiac muscle cell contraction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
negative regulation of protein targeting to membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
MAPK cascade	C-C chemokine receptor type 5	Homo sapiens (human)
dendritic cell chemotaxis	C-C chemokine receptor type 5	Homo sapiens (human)
calcium ion transport	C-C chemokine receptor type 5	Homo sapiens (human)
chemotaxis	C-C chemokine receptor type 5	Homo sapiens (human)
cellular defense response	C-C chemokine receptor type 5	Homo sapiens (human)
cell surface receptor signaling pathway	C-C chemokine receptor type 5	Homo sapiens (human)
G protein-coupled receptor signaling pathway	C-C chemokine receptor type 5	Homo sapiens (human)
cell-cell signaling	C-C chemokine receptor type 5	Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	C-C chemokine receptor type 5	Homo sapiens (human)
calcium-mediated signaling	C-C chemokine receptor type 5	Homo sapiens (human)
signaling	C-C chemokine receptor type 5	Homo sapiens (human)
symbiont entry into host cell	C-C chemokine receptor type 5	Homo sapiens (human)
chemokine-mediated signaling pathway	C-C chemokine receptor type 5	Homo sapiens (human)
response to cholesterol	C-C chemokine receptor type 5	Homo sapiens (human)
cellular response to lipopolysaccharide	C-C chemokine receptor type 5	Homo sapiens (human)
negative regulation of macrophage apoptotic process	C-C chemokine receptor type 5	Homo sapiens (human)
inflammatory response	C-C chemokine receptor type 5	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	C-C chemokine receptor type 5	Homo sapiens (human)
immune response	C-C chemokine receptor type 5	Homo sapiens (human)
cell chemotaxis	C-C chemokine receptor type 5	Homo sapiens (human)
gastrin-induced gastric acid secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
glucose metabolic process	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
heart development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
rhythmic behavior	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of heart contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of blood pressure	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of heart rate	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
iodide transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
erythrocyte differentiation	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
intracellular chloride ion homeostasis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
response to insulin	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
social behavior	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
corticosterone secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
inner ear morphogenesis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
inner ear development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
intestinal absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
auditory receptor cell development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of gastric acid secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
stomach development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
renal absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
renal sodium ion absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to cAMP	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to epinephrine stimulus	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
adrenergic receptor signaling pathway	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cardiac muscle cell contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
atrial cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cochlea development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
non-motile cilium assembly	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac conduction system development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac ventricle development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
brainstem development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
telencephalon development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cerebellum development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cellular response to calcium ion	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell to bundle of His cell communication	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium channel regulator activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
telethonin binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
protein-containing complex binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
transmembrane transporter binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
virus receptor activity	C-C chemokine receptor type 5	Homo sapiens (human)
actin binding	C-C chemokine receptor type 5	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	C-C chemokine receptor type 5	Homo sapiens (human)
chemokine receptor activity	C-C chemokine receptor type 5	Homo sapiens (human)
protein binding	C-C chemokine receptor type 5	Homo sapiens (human)
coreceptor activity	C-C chemokine receptor type 5	Homo sapiens (human)
C-C chemokine receptor activity	C-C chemokine receptor type 5	Homo sapiens (human)
C-C chemokine binding	C-C chemokine receptor type 5	Homo sapiens (human)
identical protein binding	C-C chemokine receptor type 5	Homo sapiens (human)
chemokine (C-C motif) ligand 5 binding	C-C chemokine receptor type 5	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein phosphatase 1 binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
outward rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein kinase A catalytic subunit binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein kinase A regulatory subunit binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
transmembrane transporter binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
calmodulin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
fibroblast growth factor binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
enzyme binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein kinase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein domain specific binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ankyrin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nitric-oxide synthase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
scaffold protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
lysosome	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
apical plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
Z disc	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane raft	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
cell surface	C-C chemokine receptor type 5	Homo sapiens (human)
endosome	C-C chemokine receptor type 5	Homo sapiens (human)
plasma membrane	C-C chemokine receptor type 5	Homo sapiens (human)
external side of plasma membrane	C-C chemokine receptor type 5	Homo sapiens (human)
cell surface	C-C chemokine receptor type 5	Homo sapiens (human)
external side of plasma membrane	C-C chemokine receptor type 5	Homo sapiens (human)
cytoplasm	C-C chemokine receptor type 5	Homo sapiens (human)
early endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
endoplasmic reticulum	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cytoplasm	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
lysosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
early endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
late endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
endoplasmic reticulum	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
basolateral plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
apical plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
transport vesicle	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cytoplasmic vesicle membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
neuron projection	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
neuronal cell body	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane raft	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
ciliary base	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
lumenal side of membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
basolateral part of cell	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
monoatomic ion channel complex	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleolus	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
endoplasmic reticulum	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cell surface	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
lateral plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sarcolemma	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1713963	Antiviral activity against HIV-1 BAL infected in human macrophages assessed as reduction in p24 production at 500 nM treated for 1 hr prior to viral infection and measured after 5 days by ELISA	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400647	Tmax in Sprague-Dawley rat at 10 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400690	Half life in dog at 0.5 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400622	Antiviral activity against CCR5-dependent HIV1 SF162 infected in human HOS cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400623	Cytotoxicity against human HOS cells after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400616	Antiviral activity against CCR5-dependent HIV1 SF162 infected in human TZM-bl cells assessed as reduction in virus infection measured after 48 hrs post infection by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400608	Drug metabolism in dog liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-1-(4-hydroxyphenyl)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mass spectrome	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400618	Therapeutic index, ratio of CC50 for human TZM-bl cells to EC50 for CCR5-dependent HIV1 SF162 infected in human TZM-bl cells	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400632	Cytotoxicity against human PM1 cells after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400665	Metabolic stability in rat hepatocytes assessed as compound remaining by UPLC/Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400650	Half life in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400605	Oral bioavailability in rat at 10 mg/kg administered as single dose	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400620	Cytotoxicity against human PBMC after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713975	Antiviral activity against HIV-1 SF162 infected in human astrocytes assessed as reduction in viral invasion by measuring decrease in Tat protein expression at 100 nM co-treated with morphine prior to viral infection and measured after 18 hrs by luciferase	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400613	Drug metabolism in rat liver cells assessed as CYP450-mediated 3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane metabolite levels by Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400612	Drug metabolism in human liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-3-(3-(3-(hydroxymethyl)-5-isopropyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(4-hydroxyphenyl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mas	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713969	Antiviral activity against HIV-1 SF162 infected in human astrocytes assessed as reduction in viral invasion by measuring decrease in Tat protein expression at 100 nM treated prior to viral infection and measured after 18 hrs by luciferase based assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1713979	Antagonist activity at CCR5 receptor in CHO cells co-expressing hMOR, CD4 and luciferase reporter assessed as inhibition of CD4-gp120 complex interaction with receptor dimer by measuring inhibition of cell-cell fusion process at 100 nM measured after co-i	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400648	AUC (0 to infinity) in Sprague-Dawley rat at 10 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400692	AUC (0 to infinity) in dog at 2 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400633	Therapeutic index, ratio of CC50 for human PM1 cells to IC50 for CCR5-dependent HIV1 Ba-L infected in human PM1 cells	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713967	Antagonist activity at CCR5 receptor in human MOLT4 cells transfected with Gqi5 assessed as inhibition of RANTES-induced calcium mobilization incubated for 15 mins prior to RANTES addition and measured for 120 secs by Fluo-4AM dye based fluorescence analy	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400629	Antiviral activity against CCR5-dependent HIV1 Ba-L infected in human HOS cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400621	Therapeutic index, ratio of CC50 for human PBMC to IC50 for CCR5-dependent HIV1 SF162 infected in human PBMC cells	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400625	Antiviral activity against CCR5-dependent HIV1 KM018 infected in human PBMC assessed as reduction in virus infection measured after 7 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713964	Antiviral activity against HIV-1 BAL infected in human PBMC assessed as reduction in p24 production at 500 nM treated for 1 hr prior to viral infection and measured after 5 days by ELISA	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400688	Cmax in dog at 2 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400662	Metabolic stability in human hepatocytes assessed as compound remaining by UPLC/Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400651	Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400631	Antiviral activity against CCR5-dependent HIV1 Ba-L infected in human PM1 cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400626	Therapeutic index, ratio of CC50 for human PBMC to IC50 for CCR5-dependent HIV1 KM018 infected in human PBMC	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400627	Antiviral activity against CCR5-dependent HIV1 Ba-L infected in human PBMC assessed as reduction in virus infection measured 7 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400624	Therapeutic index, ratio of CC50 for human HOS cells to IC50 for CCR5-dependent HIV1 SF162 infected in human HOS cells	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400611	Drug metabolism in dog liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-3-(3-(3-(hydroxymethyl)-5-isopropyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(4-hydroxyphenyl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mass	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713980	Antagonist activity at CCR5 receptor in CHO cells co-expressing hMOR, CD4 and luciferase reporter assessed as inhibition of CD4-gp120 complex interaction with receptor dimer by measuring inhibition of cell-cell fusion process at 100 nM measured after co-i	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400691	Clearance in dog at 0.5 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400603	Cmax in rat at 10 mg/kg, po administered as single dose	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400609	Drug metabolism in human liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-1-(4-hydroxyphenyl)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mass spectro	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400615	Drug metabolism in human liver cells assessed as CYP450-mediated 3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane metabolite levels by Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1713968	Displacement of [125I]MIP-1alpha from CCR5 receptor in rhesus monkey membrane incubated for 120 mins by liquid scintillation counting analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
AID1400617	Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400607	Drug metabolism in rat liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-1-(4-hydroxyphenyl)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mass spectrome	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400649	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400630	Therapeutic index, ratio of CC50 for human HOS cells to IC50 for CCR5-dependent HIV1 Ba-L infected in human HOS cells	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400610	Drug metabolism in rat liver cells assessed as CYP450-mediated 4,4-difluoro-N-((1S)-3-(3-(3-(hydroxymethyl)-5-isopropyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(4-hydroxyphenyl)propyl)cyclohexanecarboxamide metabolite levels by Q-TOF mass	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400614	Drug metabolism in dog liver cells assessed as CYP450-mediated 3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane metabolite levels by Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400693	Oral bioavailability in dog at 2 mg/kg by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400606	Antagonist activity at CCR5 (unknown origin) expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of RANTES-induced calcium flux preincubated for 10 mins followed by RANTES addition by fluo-4AM-based fluorescence assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400604	AUC in rat at 10 mg/kg, po administered as single dose	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400628	Therapeutic index, ratio of CC50 for human PBMC to IC50 for CCR5-dependent HIV1 Ba-L infected in human PBMC	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400689	Tmax in dog at 2 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400619	Antiviral activity against CCR5-dependent HIV1 SF162 infected in human PBMC assessed as reduction in virus infection measured after 7 days by luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400664	Metabolic stability in dog hepatocytes assessed as compound remaining by UPLC/Q-TOF mass spectrometric analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1400646	Cmax in Sprague-Dawley rat at 10 mg/kg, po by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
AID1654459	Drug metabolism in human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID554142	Unbound clearance in rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID554144	Oral bioavailability in rat at 10 mg/kg	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID393050	Antagonist activity at human recombinant CCR5 expressed in human HeLa-P4 cells assessed as inhibition of human HeLa-P4 cells binding to HIV1 gp160 expressing CHO cells by cell-cell fusion assay	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID320905	Antiviral activity against HIV1 RU570 by viral entry assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
AID1897764	Therapeutic index, ratio of CC50 for human PM1 cells to EC50 for antiviral activity against HIV-1 YU-2	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID393051	Antiviral activity against HIV1 Bal infected in human PM1 cells assessed as inhibition of viral replication	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID776010	Antiviral activity against Human immunodeficiency virus 1 clade O isolate I-2478B infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID776011	Antiviral activity against Human immunodeficiency virus 1 clade G isolate BZ163 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID554137	Intrinsic clearance in human liver microsomes assessed per mg of protein	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID776013	Antiviral activity against Human immunodeficiency virus 1 clade C isolate ETH2220 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID554163	Intrinsic clearance in dog liver microsomes assessed per mg of protein	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID698308	Antiviral activity against HIV1 clade C (SM145) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1897758	Antiviral activity against HIV-1 SF162 infected in human TZM-bl cells measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1897772	Therapeutic index, ratio of CC50 for human PBMC to EC50 for antiviral activity against HIV-1 KIZ006 clinical isolate	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID776061	Antiviral activity against Human immunodeficiency virus 1 clade A isolate UG273 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID776012	Antiviral activity against Human immunodeficiency virus 1 clade E isolate ID12 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID320902	Antiviral activity against HIV1 ASM80 by viral entry assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
AID395488	Apparent permeability from apical to basolateral side of human Caco-2 cells	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID499099	Antiviral activity against HIV1 UG273 clade A, R5 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1897792	Half life in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID499095	Antiviral activity against HIV1 NL4.3 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID554143	Half life in rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654488	AUC(0 to infinity) in human carrying CYP3A53/3 allele at 300 mg, po measured up to 32 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID776007	Antiviral activity against Human immunodeficiency virus 1 clade B isolate CI#15 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID698307	Antiviral activity against HIV1 clade A/E (ID12) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID698152	Antiviral activity against HIV1 clade A (UG273) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID776005	Antiviral activity against Human immunodeficiency virus 1 clade B isolate BaL infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID250740	Mean decrease in viral load in humans after administration of 100 mg twice a day; expressed as log10 reduction	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	New approaches toward anti-HIV chemotherapy.
AID1207345	Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1654469	Drug metabolism in human liver microsomes assessed as formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID776006	Antiviral activity against Human immunodeficiency virus 1 clade B isolate CI#19 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID1897765	Therapeutic index, ratio of CC50 for human PM1 cells to EC50 for antiviral activity against HIV-1 SF162	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1207529	Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID397744	Inhibition of human ERG channel at 300 uM	2009	Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14	Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID1897757	Cytotoxicity against human PBMC cells incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1191661	Antiviral activity against HIV1 infected in human SupT1 cells exposed to supernatant from HIV1 infected human 293T cells incubated for 48 hrs by firefly luciferase assay based single-cycle HIV1 replication assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
AID1897762	Antiviral activity against HIV-1 Ba-L infected in human PM1 cells measured after 48 hrs incubation by ELISA based p24 antigen assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1654478	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1654486	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A53/3-mediated formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID499097	Antiviral activity against HIV1 BZ167 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID465010	Displacement of [128I]RANTES from human CCR5 receptor coexpressed with Galphai6 in CHO cells after 2 hrs by scintillation counting	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
AID393053	Metabolic stability in human liver microsomes assessed as clearance measured per mg of protein	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID710734	Antagonist activity against CXCR4 expressed in U87.CD.CXCR4 cells assessed as inhibition of CXCL12-induced calcium signaling incubated for 10 mins by FLIPR	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID479416	Antiviral activity against HIV1 NL4-3 infected in human JC53-BL cells assessed as luciferase activity after 3 days post infection	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.
AID776014	Antiviral activity against Human immunodeficiency virus 1 clade B isolate US2 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID554152	Absorption in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1897759	Antiviral activity against HIV-1 YU-2 infected in human TZM-bl cells measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1353545	Displacement of [125I]-RANTES from CCR5 in mouse NIH/3T3 cells after 1 hr	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Recent updates for designing CCR5 antagonists as anti-retroviral agents.
AID707904	Binding affinity to CCR5	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Chemokine receptor antagonists.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1654470	Drug metabolism in CYP3cide-treated human liver microsomes assessed as formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897767	Antiviral activity against HIV-1 KM018 clinical isolate infected in human PBMC measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID393056	Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells at 300 nM	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID1654457	Drug metabolism in human liver microsomes assessed as formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1207315	Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1654483	Drug metabolism in human liver microsomes assessed as CYP3A51/1-mediated formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID554139	Antiviral activity against HIV Ba-L infected in PBMC	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1897789	AUC (0 to infinitive) in Sprague-Dawley rat at 10 mg/kg, po measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID270504	Distribution coefficient, log D of the compound	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
AID465011	Antiviral activity against CCR5-tropic recombinant HIV1 NLBal virus infected in JC53-BL cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
AID1654474	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1207435	Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID1654485	Drug metabolism in human liver microsomes assessed as CYP3A53/3-mediated formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1654489	AUC(0 to infinity) in human carrying CYP3A51/3 allele at 300 mg, po measured up to 32 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1654458	Drug metabolism in CYP3cide-treated human liver microsomes assessed as formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897803	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID320903	Antiviral activity against HIV1 BaL by viral entry assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
AID1897761	Therapeutic index, ratio of CC50 for human HOS-CD4-CCR5 cells to EC50 for antiviral activity against HIV-1 Ba-L	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID554141	Clearance in rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID270500	Inhibition of [3H]dofetilide binding to HERG expressed in HEK293 cells at 300 nM	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
AID776009	Antiviral activity against Human immunodeficiency virus 1 clade B isolate SF162 infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1654472	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897802	Inhibition of CYP2D6 (unknown origin)	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID776008	Antiviral activity against Human immunodeficiency virus 1 clade B isolate Ada infected in PHA-stimulated human PBMC after 10 days by ELISA	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
AID1065006	Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 JR-FL-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.
AID554058	Tmax in rat at 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1897771	Antiviral activity against HIV-1 KIZ006 clinical isolate infected in human PBMC measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1594898	Half life in human liver microsomes	2019	Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11	Applications of Deuterium in Medicinal Chemistry.
AID1654475	Drug metabolism in human liver microsomes assessed as formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897786	Tmax in Sprague-Dawley rat at 10 mg/kg, po measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID652438	Binding affinity to CCR5	2011	ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7	Screening for GPCR Ligands Using Surface Plasmon Resonance.
AID1654463	Drug metabolism in human liver microsomes assessed as formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID320904	Antiviral activity against HIV1 97-ZA-003 by viral entry assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
AID270503	Antiviral activity against HIV BaL in PM1 cell	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
AID1207375	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID395483	Antagonist activity at human recombinant CCR5 expressed in human HeLa-P4 cells assessed as inhibition of human HeLa-P4 cells binding to HIV1 gp160 expressing CHO cells by cell-cell fusion assay	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID499101	Antiviral activity against HIV1 ETH2220 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1897751	Antagonist activity at CCR5 (unknown origin) expressed in HEK293 cells co-expressing Galpha16 assessed as intracellular calcium change incubated for 15 mins by Fluo-4 AM calcium flux assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1654481	Drug metabolism in human liver microsomes assessed as formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897797	Half life in Sprague-Dawley rat at 1 mg/kg, iv measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID393054	Dissociation constant, pKa of the compound	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID1654482	Drug metabolism in CYP3cide-treated human liver microsomes assessed as formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1207563	Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID554132	Antagonist activity at CCR5 receptor expressed in HeLa-P4 cells co-expressing CD4 assessed as inhibition of infusion to HIV gp120 expressed in CHO-tat10 cells after 20 hrs by cell-cell fusion assay	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID698149	Antiviral activity against HIV1 clade G (BCF-DIOUM) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1191659	Antagonist activity against CCR5 (unknown origin) expressed in CHO cells co-expressing Galpha16 incubated for 10 mins assessed as inhibition of RANTES-induced calcium mobilization	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
AID554060	fCmax in rat at 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID270506	Inhibition of [3H]dofetilide binding to HERG expressed in HEK293 cells at 1000 nM	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
AID1897773	Antiviral activity against HIV-1 YU-2 (G140S/Q148H) infected in human TZM-bl cells measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID395486	Antiviral activity against HIV1 BAL assessed as inhibition of viral replication	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID1897763	Therapeutic index, ratio of CC50 for human PM1 cells to EC50 for antiviral activity against HIV-1 Ba-L	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1207469	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID1207285	Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID1897760	Antiviral activity against HIV-1 Ba-L infected in human HOS-CD4-CCR5 cells measured after 48 hrs incubation by ELISA based p24 antigen assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID395489	Apparent permeability from basolateral to apical side of human Caco-2 cells	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID249028	Inhibitory concentration against human immunodeficiency virus isolates utilizing C-C chemokine receptor type 5 for cell entry	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	New approaches toward anti-HIV chemotherapy.
AID698150	Antiviral activity against HIV1 clade F (BZ162) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1654465	Drug metabolism in human liver microsomes assessed as CYP3A51/1-mediated formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID499096	Antiviral activity against HIV1 Ba-L in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1654464	Drug metabolism in CYP3cide-treated human liver microsomes assessed as formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID554145	Absorption in rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID554149	Volume of distribution in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID698310	Antiviral activity against HIV1 clade D (UG270) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1897769	Antiviral activity against HIV-1 KIZ001 clinical isolate infected in human PBMC measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID698309	Antiviral activity against HIV1 clade C (DJ259) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1654471	Drug metabolism in human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1065005	Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 92RW-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.
AID1370975	Inhibition of CCR5 in human TZM-bl cells infected with HIV1 Bal R5 assessed as antiviral activity by measuring reduction in viral infection pre-incubated with cells followed by viral infection measured after 3 days by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase.
AID554151	Oral bioavailability in dog at 1 mg/kg	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654480	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID707884	Antiviral activity against CCR5-tropic HIV1	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Chemokine receptor antagonists.
AID554146	Plasma protein binding in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID449003	Antiviral activity against HIV1 Ba-L infected in HOS cells assessed as inhibition of viral infection	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents.
AID554055	Tmax in dog at 0.5 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1897768	Therapeutic index, ratio of CC50 for human PBMC to EC50 for antiviral activity against HIV-1 KM018 clinical isolate	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1654473	Drug metabolism in human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,3S)-3-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID710735	Inhibition of CXCL-12'AF647 binding to CXCR4 in human SUPT1 cells incubated for 15 mins by FACS	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID1808908	Antagonist activity at human CCR5 receptor expressed in HEK293 cells co-expressing Galpha15 assessed as inhibition of RNATES-induced intracellular calcium flux measured after 10 mins by FLIPR calcium mobilization assay	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID395485	Metabolic stability in human liver microsomes assessed as clearance measured per mg of protein	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID1897752	Antiviral activity against HIV-1 Ba-L infected in human TZM-bl cells measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1897804	Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1242368	Inhibition of CXCR4 in human Jurkat cells assessed as reduction in HIV-Nef-M1-induced mitochondrial membrane depolarization at 0.01 to 100 uM by JC1 dye based fluorescence depolarization assay	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
AID1207499	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID625293	Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID554147	Clearance in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1897756	Cytotoxicity against human HOS-CD4-CCR5 cells incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID250714	Mean decrease in viral load in humans after administration of 25 mg once a day; expressed as log 10 reduction	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	New approaches toward anti-HIV chemotherapy.
AID1121816	Antagonist activity at CCR5 in Gqi5 transfected human MOLT4 cells assessed as inhibition of RANTES-stimulated Ca2+ influx preincubated for 15 mins followed by DAMGO challenge	2013	MedChemComm, May-01, Volume: 4, Issue:5	A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
AID1897766	Antiviral activity against HIV-1 IIIB infected in human TZM-bl cells measured after 48 hrs incubation by luciferase based analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1897801	Inhibition of CYP2C19 (unknown origin)	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID707908	Lipophilicity, log P of the compound	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Chemokine receptor antagonists.
AID479402	Binding affinity at CCR5 receptor by radiolabeled RANTES binding assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.
AID395484	Lipophilicity, log D at pH 7.4	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID554136	Apparent permeability from basolateral to apical side of human Caco2 cells	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654468	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A53/3-mediated formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1207405	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID1654461	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1121818	Displacement of [125I]-MIP-1alpha from CCR5 in rhesus monkey Chem-1 cell membranes after 120 mins by liquid scintillation counting analysis	2013	MedChemComm, May-01, Volume: 4, Issue:5	A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
AID554150	Half life in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654479	Drug metabolism in human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1654490	AUC(0 to infinity) in human carrying CYP3A51/1 allele at 300 mg, po measured up to 32 hrs	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID499100	Antiviral activity against HIV1 US2 clade B, R5 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID397746	Lipophilicity, log D of the compound	2009	Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14	Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID1654466	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A51/1-mediated formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897785	Cmax in Sprague-Dawley rat at 10 mg/kg, po measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID395491	Volume of distribution in iv dosed Sprague-Dawley rat	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID1897799	Inhibition of CYP1A2 (unknown origin)	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1897753	Cytotoxicity against human TZM-bl cells incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID579722	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1.
AID698151	Antiviral activity against HIV1 clade B (BaL) infected in human PBMCs assessed as inhibition of p24 antigen production by ELISA	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID554140	Plasma protein binding in rat at 1 mg/kg, iv and 10 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID395490	Clearance in iv dosed Sprague-Dawley rat	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID393052	Lipophilicity, log D at pH 7.4	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
AID1897800	Inhibition of CYP2C9 (unknown origin)	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID554056	fCmax in dog at 0.5 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1062970	Inhibition of CCR5 (unknown origin) expressed in CHO cells assessed as inhibition of RANTES-induced intracellular Ca2+ mobilization after 10 mins by Fluo-4 AM staining-based fluorescence assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.
AID1654484	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A51/1-mediated formation of hydroxymethyl-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1062969	Antiviral activity against HIV-1 infected in human SupT1 cells assessed as inhibition of viral infectivity after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.
AID710729	Antagonist activity against CXCR5 expressed in U87.CD.CXCR5 cells assessed as inhibition of CCL3L1-induced calcium signaling incubated for 10 mins by FLIPR	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID554162	Intrinsic clearance in rat liver microsomes assessed per mg of protein	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654462	Drug metabolism in human liver microsomes assessed as CYP3A53/3-mediated formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897755	Cytotoxicity against human PM1 cells incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID499102	Antiviral activity against HIV1 DJ259 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID395492	Half life in iv dosed Sprague-Dawley rat	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
AID1897798	Clearance in Sprague-Dawley rat at 1 mg/kg, iv measured upto 24 hrs	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1897770	Therapeutic index, ratio of CC50 for human PBMC to EC50 for antiviral activity against HIV-1 KIZ001 clinical isolate	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID1370972	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability after 2 days by CCK-8 assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase.
AID320901	Antiviral activity against HIV1 JRCSF by viral entry assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
AID1654460	Drug metabolism in CYP3cide-treated human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,2S)-2-OH-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID499098	Antiviral activity against HIV1 strain I-2496 in human PBMC assessed as p24 antigen level by ELISA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID554134	Displacement of [3H]-dofetilide from human ERG expressed in HEK293 cells at 300 nM	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID554148	Unbound clearance in dog at 0.5 mg/kg, iv and 1 mg/kg, po	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1654477	Drug metabolism in human liver microsomes assessed as CYP3A51/1-mediated formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1654467	Drug metabolism in human liver microsomes assessed as CYP3A53/3-mediated formation of (1R,2R)-2-OH-maraviroc at 8 uM incubated for 15 mins in presence of ketoconazole by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1654476	Drug metabolism in CYP3cide-treated human liver microsomes assessed as formation of (1S,3R)-3-OH-MVC-maraviroc at 8 uM incubated for 15 mins by LC-MS/MS method	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Effective Application of Metabolite Profiling in Drug Design and Discovery.
AID1897754	Therapeutic index, ratio of CC50 for human TZM-bl cells to EC50 for antiviral activity against HIV-1 Ba-L	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
AID554135	Apparent permeability from apical to basolateral side of human Caco2 cells	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID1065007	Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 YU2-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.
AID1065004	Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 MGC26-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.
AID1121815	Binding affinity to CCR5/MOR in human astrocytes assessed as inhibition of R5 HIV-1 SF162 infection by measuring Tat protein expression at 100 nM preincubated for 30 to 60 mins followed by viral infection measured after 18 hrs by luciferase reporter gene	2013	MedChemComm, May-01, Volume: 4, Issue:5	A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1820207	Cytotoxicity against human GHOST CCR5 cells assessed as reduction in cell viability measured after 6 days by XTT assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
AID1820204	Antagonist activity at CCR5 (unknown origin) expressed in HOS cells co-expressing Gqi-5 assessed as inhibition CCL5-stimulated Ca2+ mobilization by calcium mobilization assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
AID1820208	Therapeutic index, ratio of TC50 for human GHOST CCR5 cells to EC50 for inhibition of CCR5-mediated HIV-1 Bal entry in human GHOST CCR5 cells	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
AID1820206	Inhibition of CCR5-mediated HIV-1 Bal entry in human GHOST CCR5 cells assessed as decrease in viral reverse transcriptase activity by measuring [3H]thymidine triphosphate incorporation measured after 60 to 90 mins by scintillation counting analysis	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
AID1346815	Human CCR5 (Chemokine receptors)	2005	Biochemical pharmacology, Dec-19, Volume: 71, Issue:1-2	Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	141 (19.00)	29.6817
2010's	515 (69.41)	24.3611
2020's	86 (11.59)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	124 (15.80%)	5.53%
Reviews	93 (11.85%)	6.00%
Case Studies	30 (3.82%)	4.05%
Observational	9 (1.15%)	0.25%
Other	529 (67.39%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (139)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I) [NCT01133210]	Phase 1	27 participants (Actual)	Interventional	2011-01-31	Completed
Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19 [NCT04710199]	Phase 2	44 participants (Actual)	Interventional	2021-02-23	Completed
A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy [NCT00981773]	Phase 4	18 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Recruitment problem)
A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1 [NCT01345630]	Phase 3	813 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to See termination reason in detailed description.)
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 [NCT01235013]	Phase 4	60 participants (Anticipated)	Interventional		Not yet recruiting
Incidence And Risk Factors For Acquired Immune Deficiency Syndrome (AIDS) Defining And Non-AIDS Defining Malignancies, And Other AIDS Defining Illnesses In The EuroSIDA Study [NCT01329783]		1,181 participants (Actual)	Observational	2007-04-30	Completed
The Effects of Maraviroc Versus Efavirenz in Combination With Zidovudine/Abacavir on the CD4/CD8 Ratio in Treatment-naïve HIV-infected Individuals [NCT03178084]	Phase 3	721 participants (Actual)	Interventional	2014-10-15	Completed
A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH) [NCT05470491]	Phase 1/Phase 2	265 participants (Anticipated)	Interventional	2023-01-26	Suspended(stopped due to On administrative hold for interim data analysis.)
Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring [NCT01363037]	Phase 1	48 participants (Actual)	Interventional	2011-11-30	Completed
A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-T [NCT00098748]	Phase 2/Phase 3	190 participants (Actual)	Interventional	2004-11-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infe [NCT00098306]	Phase 2/Phase 3	601 participants (Actual)	Interventional	2004-11-30	Completed
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication [NCT02486510]	Early Phase 1	7 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Futility criteria)
A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects [NCT02480894]	Phase 1	112 participants (Actual)	Interventional	2015-07-07	Completed
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation [NCT00948753]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2009-06-30	Completed
Safety of Maraviroc for Post-stroke Depression (Proof-of-concept) [NCT05932550]	Phase 2	10 participants (Actual)	Interventional	2020-08-04	Completed
Pilot Study Evaluating Maraviroc (Celsentri®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO [NCT00944541]	Phase 2	60 participants (Actual)	Interventional	2009-09-30	Completed
Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2 [NCT04435522]	Phase 1	9 participants (Actual)	Interventional	2020-10-01	Completed
DRUG USE INVESTIGATION FOR HIV INFECTION PATIENTS OF MARAVIROC (REGULATORY POST MARKETING COMMITMENT PLAN). [NCT00864474]		68 participants (Actual)	Observational	2010-03-31	Completed
Open-Label, Fixed-Sequence, Crossover Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects [NCT01140412]	Phase 1	14 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to The trial prematurely terminated on November 1, 2010, due to healthy volunteer participants experiencing non-serious fosamprenavir-related skin rash.)
Non-Interventional Study Of Celsentri® In Treatment Experienced Patients Infected With CCR5 Tropic HIV-1 [NCT00850395]		79 participants (Actual)	Observational	2009-07-31	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Saliva, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Maraviroc [NCT00775294]	Phase 1	14 participants (Actual)	Interventional	2008-05-31	Completed
Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH [NCT01585753]		34 participants (Actual)	Observational	2012-06-30	Completed
Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial [NCT01367210]	Phase 4	165 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Because a higher rate of virological failures in study versus control arm.)
Open-Label, Fixed-Sequence Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects [NCT01290211]	Phase 1	28 participants (Actual)	Interventional	2011-04-30	Completed
Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus [NCT01291459]	Phase 2	40 participants (Anticipated)	Interventional	2011-09-30	Active, not recruiting
A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy [NCT01190293]	Phase 4	12 participants (Actual)	Interventional	2010-01-31	Completed
Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients [NCT03708861]	Phase 3	0 participants (Actual)	Interventional	2016-01-31	Withdrawn
Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection [NCT02778204]	Phase 1	47 participants (Actual)	Interventional	2017-06-05	Completed
Maraviroc to Augment Rehabilitation Outcomes After Stroke [NCT03172026]	Phase 2/Phase 3	2 participants (Actual)	Interventional	2019-08-01	Terminated(stopped due to Poor recruitment for each site, partly related to Covid epidemic.)
Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differen [NCT01348308]	Phase 3	407 participants (Actual)	Interventional	2011-09-30	Completed
A Pilot Trial of Maraviroc for Treatment of Subjects on Antiretroviral Therapy With Suboptimal CD4 T-cell Count Recovery Despite Sustained Virologic Suppression [NCT00709111]		34 participants (Actual)	Interventional	2009-01-31	Completed
A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers [NCT00771823]	Phase 1	16 participants (Actual)	Interventional	2008-05-31	Completed
Safety and Efficacy of Maraviroc-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Donor Transplantation [NCT02799888]	Phase 2	40 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Maraviroc and NeuroAIDS Pathogenesis [NCT02159027]	Phase 2/Phase 3	48 participants (Actual)	Interventional	2015-06-30	Completed
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis [NCT02134717]		3 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Poor recruitment)
The Role of Home Packs of HIV Post-Exposure Prophylaxis for Sexual Exposure (PEPSE) to Improve the Speed and Appropriate Uptake of PEPSE in High Risk Individuals [NCT04965662]	Phase 4	139 participants (Actual)	Interventional	2018-01-01	Completed
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients [NCT00981318]	Phase 4	3 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to unable to enroll expected number of subjects)
A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infecte [NCT00098293]	Phase 3	916 participants (Actual)	Interventional	2004-11-30	Completed
IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults [NCT00977756]		168 participants (Actual)	Observational	2002-08-31	Completed
A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India [NCT00992654]		0 participants	Expanded Access		No longer available
AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS [NCT00665561]		2,500 participants (Actual)	Observational	2008-03-31	Completed
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 [NCT00801515]		0 participants	Expanded Access	2009-08-31	No longer available
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care [NCT00440271]	Phase 3	33 participants (Actual)	Interventional	2007-02-28	Terminated
Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects [NCT01056874]	Phase 1	12 participants (Actual)	Interventional	2010-03-31	Completed
Estudio Comparativo de Dos métodos Para Predecir el Uso de Co-receptores Por el Virus de la Inmunodeficiencia 1 (HIV-1): el Ensayo fenotípico (Trofile ESTA®) y la Respuesta virológica a Corto Plazo a un Antagonista de CCR5 [NCT01060618]	Phase 2/Phase 3	58 participants (Actual)	Interventional	2009-05-31	Completed
Surrogate Marker For Tropism-A Multi-Center, Open Label, Pilot Study [NCT00496782]	Phase 1	16 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to See Detailed Description)
Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression [NCT00966329]	Phase 4	30 participants (Actual)	Interventional	2009-10-31	Completed
A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration. [NCT00643643]	Phase 2	41 participants (Actual)	Interventional	2002-10-31	Completed
Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1 [NCT00827112]	Phase 2	129 participants (Actual)	Interventional	2009-03-31	Completed
A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To [NCT00783484]	Phase 1	37 participants (Actual)	Interventional	2008-10-31	Completed
A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02) [NCT00703586]	Phase 1	8 participants (Actual)	Interventional	2007-09-30	Completed
AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2 - <18 YEARS OF AGE [NCT00791700]	Phase 2	103 participants (Actual)	Interventional	2009-04-22	Active, not recruiting
An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects [NCT00666705]	Phase 4	18 participants (Actual)	Interventional	2008-02-29	Completed
A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B [NCT00782301]	Phase 4	0 participants (Actual)	Interventional	2009-03-31	Withdrawn
Steady State Pharmacokinetics (PK) of Fosamprenavir (FPV) Alone or in Combination With Low Dose Ritonavir (/r) (1400mg BID, 1400mg/100mg QD or 700/100mg BID) and the Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC) 300mg BID in Healthy Voluntee [NCT00764465]	Phase 2	45 participants (Actual)	Interventional	2008-10-31	Completed
CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics [NCT00666055]		11 participants (Actual)	Observational	2008-03-31	Completed
Maraviroc Immune Recovery Study, A Multicenter, Randomized, Placebo-controlled, Exploratory Mechanistic Study Into the Role of Maraviroc on Immune Recovery [NCT00875368]	Phase 4	85 participants (Actual)	Interventional	2009-02-28	Completed
An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers [NCT00821535]	Phase 1	12 participants (Actual)	Interventional	2009-02-28	Completed
Maraviroc Abacavir STudy - Effect on Endothelial Recovery [NCT01389063]	Phase 4	24 participants (Anticipated)	Interventional	2012-01-31	Recruiting
CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients [NCT00988780]		276 participants (Anticipated)	Interventional	2009-12-31	Active, not recruiting
Pilot Study Of The Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy [NCT00795444]	Phase 2	10 participants (Actual)	Interventional	2008-03-31	Completed
The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen [NCT00537394]	Phase 3	517 participants (Actual)	Interventional	2008-01-31	Completed
An Investigation Into The Effects Of Food And Dose Regimen On Viral Load Response In HIV Infected Patients On Short-Term Monotherapy With UK-427,857 (Maraviroc) [NCT00634959]	Phase 2	37 participants (Actual)	Interventional	2003-07-31	Completed
A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) [NCT03274804]	Phase 1	20 participants (Actual)	Interventional	2018-04-01	Completed
An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function [NCT00717067]	Phase 4	30 participants (Actual)	Interventional	2008-07-31	Completed
Adding Maraviroc to the HAART Regimen of HIV-infected Patients Who Are Well Controlled, and the Effect on CD4 Lymphocyte Counts [NCT02934022]		25 participants (Actual)	Interventional	2012-06-30	Completed
A Multicenter, Open Label, Expanded Access Trial Of Maraviroc [NCT00426660]	Phase 3	1,047 participants (Actual)	Interventional	2007-02-28	Completed
Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM) [NCT01033760]	Phase 3	90 participants (Actual)	Interventional	2010-04-30	Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate [NCT00427934]	Phase 2	128 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to See Detailed Description.)
Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens [NCT01049204]	Phase 4	48 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to The data from the first 48 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infe [NCT00098722]	Phase 2/Phase 3	474 participants (Actual)	Interventional	2004-12-31	Completed
A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. [NCT01013987]	Phase 4	60 participants (Anticipated)	Interventional	2010-02-28	Recruiting
LUMINESCENCE-001 Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer [NCT04721301]	Phase 1	50 participants (Actual)	Interventional	2017-01-15	Completed
Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites [NCT01980329]	Phase 1	24 participants (Actual)	Interventional	2013-01-31	Completed
Randomized, Double-blinded, Controlled Trial of Intensive HAART Including Raltegravir, and Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals During the Acute/Early Infection [NCT01154673]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2011-11-30	Completed
A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry®-Containing Regimen, Switching Them to Once-daily Selzentry® (600mg qd) Plus the Same 2 NRTIs Previously Administered [NCT01866267]	Phase 4	31 participants (Actual)	Interventional	2013-01-31	Completed
A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C [NCT02881762]	Phase 4	10 participants (Actual)	Interventional	2017-06-01	Completed
[NCT01680536]	Phase 4	19 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects [NCT01348763]	Phase 1	13 participants (Actual)	Interventional	2011-10-31	Completed
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus [NCT01327547]	Phase 4	138 participants (Actual)	Interventional	2011-05-18	Completed
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure [NCT00735072]	Phase 4	45 participants (Actual)	Interventional	2008-09-30	Completed
A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc [NCT00478231]	Phase 3	209 participants (Actual)	Interventional	2007-07-31	Completed
Maraviroc Compassionate Use [NCT00719823]	Phase 3	0 participants (Actual)	Interventional	2008-08-31	Withdrawn
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine. [NCT00808002]	Phase 3	30 participants (Actual)	Interventional	2009-02-28	Completed
[NCT00844519]	Phase 3	52 participants (Actual)	Interventional	2010-01-31	Completed
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile [NCT00993148]	Phase 2	25 participants (Actual)	Interventional	2010-05-31	Completed
Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well-Controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of cART [NCT01384682]	Phase 4	399 participants (Actual)	Interventional	2011-08-31	Completed
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults [NCT02346084]	Phase 1	19 participants (Actual)	Interventional	2015-01-31	Completed
Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL). [NCT01420523]	Phase 2	48 participants (Actual)	Interventional	2011-12-31	Terminated
Safety Study of Maraviroc's Effect on Human Osteoclasts [NCT01428986]		16 participants (Actual)	Observational	2009-11-30	Completed
Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients. [NCT00884858]	Phase 4	100 participants (Actual)	Interventional	2009-04-30	Completed
A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia [NCT01275625]	Phase 4	98 participants (Actual)	Interventional	2011-06-30	Completed
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy [NCT00870363]	Phase 4	44 participants (Actual)	Interventional	2009-04-30	Completed
Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2 [NCT01068873]	Phase 4	1 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to Poor enrollment)
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence [NCT03218592]	Phase 4	36 participants (Actual)	Interventional	2017-06-28	Completed
A Double-Blind, Randomised, Placebo-Controlled Phase I Trial to Compare the Pharmacokinetics of Maraviroc and Dapivirine Following Application of Maraviroc Vaginal Vaginal Gel, 0.1% 2.5g, Dapivirine Vaginal Gel, 0.05%, 2.5g and Maraviroc 0.1% + Dapivirine [NCT01242579]	Phase 1	0 participants (Actual)	Interventional	2011-01-31	Withdrawn(stopped due to In order to focus efforts on the combination ring formulation, IPM decided not to move forward with this trial.)
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) [NCT01276236]	Phase 2	13 participants (Actual)	Interventional	2011-03-09	Completed
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure [NCT02961829]		30 participants (Actual)	Interventional	2015-07-31	Completed
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients [NCT02741323]	Phase 2	97 participants (Actual)	Interventional	2017-01-01	Completed
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression [NCT00976404]	Phase 2	28 participants (Actual)	Interventional	2009-11-30	Completed
Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA [NCT00987948]	Phase 2	15 participants (Actual)	Interventional	2010-01-31	Completed
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC [NCT01533272]	Phase 4	240 participants (Actual)	Interventional	2012-02-29	Completed
A Phase II, Randomized Trial of Open-Label Truvada With Darunavir/Ritonavir Versus Multiclass Therapy With Truvada, Darunavir/Ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects [NCT00525733]		40 participants (Actual)	Interventional	2007-10-31	Completed
Switch to Maraviroc and Integrase Strand Transfer Inhibitor Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens [NCT01896921]	Phase 3	7 participants (Actual)	Interventional	2013-09-30	Completed
A Phase II Study to Assess the Efficacy of Maraviroc in Prophylaxis of GVHD in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic SCT From Unrelated Donors [NCT01785810]	Phase 2	37 participants (Actual)	Interventional	2013-02-28	Completed
The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers [NCT01627717]	Phase 1	11 participants (Actual)	Interventional	2012-06-30	Completed
Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N [NCT01637233]		28 participants (Actual)	Observational	2012-06-30	Completed
Maraviroc Switch Collaborative Study Renal Substudy [NCT01637259]	Phase 4	76 participants (Actual)	Interventional	2012-06-30	Completed
PILOT STUDY OF PROTECTION AGAINST ex Vivo HIV INFECTION IN RECTAL MUCOSA IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF MARAVIROC [NCT01719627]	Phase 1	10 participants (Actual)	Interventional	2012-10-31	Completed
Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial) [NCT01736813]		12 participants (Actual)	Observational	2012-11-30	Completed
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women [NCT01749566]	Phase 1	31 participants (Actual)	Interventional	2012-12-31	Completed
A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc [NCT00853840]	Phase 4	18 participants (Actual)	Interventional	2008-04-30	Completed
The Penetration of Maraviroc Into the Central Nervous System in HIV-1 Infected Subjects on Stable Antiretroviral Therapy; a Phase I Pharmacokinetic Study [NCT00982878]	Phase 1	13 participants (Actual)	Interventional	2009-09-30	Completed
A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers [NCT02625207]	Phase 1	47 participants (Actual)	Interventional	2015-11-06	Completed
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women [NCT02333045]		4 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.)
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic [NCT01400412]	Phase 2	262 participants (Actual)	Interventional	2012-01-17	Completed
Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment [NCT04966429]	Phase 2	150 participants (Anticipated)	Interventional	2021-05-01	Recruiting
A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Administered Concurrently in Healthy Adult Subjects [NCT01597648]	Phase 1	42 participants (Actual)	Interventional	2011-11-30	Completed
Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects [NCT01597895]	Phase 1	14 participants (Actual)	Interventional	2012-07-31	Completed
The CAMAROS Trial: The Canadian Maraviroc RCT To Augment Rehabilitation Outcomes After Stroke [NCT04789616]	Phase 2	120 participants (Anticipated)	Interventional	2022-09-15	Recruiting
Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. [NCT03402815]	Phase 4	22 participants (Actual)	Interventional	2015-01-01	Completed
A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV [NCT02519777]	Phase 4	191 participants (Actual)	Interventional	2016-04-21	Completed
MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity [NCT03163277]	Phase 4	38 participants (Actual)	Interventional	2017-05-15	Terminated(stopped due to Sloww accrual and COVID-19 related problems (impossible to perform LPs))
A Multicentre, 48 Week Randomised Controlled Factorial Trial of Adding Maraviroc and/or Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy. [NCT03129113]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2017-03-01	Completed
A Feasibility Study to Assess Protection of Vaginal and Cervical Tissues From Ex-Vivo HIV-1 Challenge Following Oral Administration of Maraviroc and Tenofovir [NCT02039323]	Phase 1	6 participants (Actual)	Interventional	2014-02-28	Completed
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART [NCT00624195]	Phase 2/Phase 3	59 participants (Actual)	Interventional	2007-03-31	Completed
Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients [NCT01204905]		7 participants (Actual)	Interventional	2010-09-30	Completed
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression [NCT00925756]	Phase 4	32 participants (Actual)	Interventional	2008-10-20	Completed
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc [NCT01894776]	Phase 1	15 participants (Actual)	Interventional	2013-06-30	Completed
A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203; Progress I) [NCT02208037]	Phase 2	279 participants (Actual)	Interventional	2014-08-31	Completed
The Effect of Sirolimus Plus Maraviroc on the Expression of Chemokine Receptor 5 (CCR5) and the HIV-1 Viral Reservoir in HIV-Infected Renal Transplant Recipients [NCT02990312]	Phase 4	0 participants (Actual)	Interventional	2017-05-01	Withdrawn(stopped due to Lack of enrollment)
A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Maraviroc in HIV Virally Suppressed Patients With Cognitive Impairment [NCT01449006]	Phase 4	19 participants (Actual)	Interventional	2011-10-31	Completed
Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19). [NCT04441385]	Phase 2	60 participants (Actual)	Interventional	2020-06-26	Terminated(stopped due to lack of viability)
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W [NCT02302547]	Phase 3	224 participants (Actual)	Interventional	2014-12-31	Completed
"Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19" [NCT04475991]	Phase 2	19 participants (Actual)	Interventional	2021-07-13	Terminated(stopped due to No more patients complying the selection criteria were available for recruitment)
A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Expo [NCT01505114]	Phase 2	594 participants (Actual)	Interventional	2012-06-30	Completed
Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients [NCT02167451]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to slow recruitment and no further drug supply)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00098293 (17) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96
NCT00098293 (17) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
NCT00098293 (17) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96
NCT00098293 (17) [back to overview]	Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
NCT00098293 (17) [back to overview]	Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels
NCT00098293 (17) [back to overview]	Time to Virologic Failure
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96
NCT00098293 (17) [back to overview]	Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
NCT00098293 (17) [back to overview]	Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
NCT00098293 (17) [back to overview]	Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96
NCT00098293 (17) [back to overview]	Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96
NCT00098293 (17) [back to overview]	Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
NCT00098293 (17) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96
NCT00098306 (18) [back to overview]	Time to Virological Failure
NCT00098306 (18) [back to overview]	Change From Baseline in CD4 Cell Count at Week 24 and 48
NCT00098306 (18) [back to overview]	Change From Baseline in CD8 Cell Count at Week 24 and 48
NCT00098306 (18) [back to overview]	Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24
NCT00098306 (18) [back to overview]	Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline
NCT00098306 (18) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24
NCT00098306 (18) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
NCT00098306 (18) [back to overview]	Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure at Week 48
NCT00098306 (18) [back to overview]	Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24
NCT00098306 (18) [back to overview]	Number of Participants With Genotypic Susceptibility Scores (GSS) and Phenotypic Susceptibility Score (PSS) at Screening
NCT00098306 (18) [back to overview]	Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening
NCT00098306 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL or With at Least 0.5 log10 Decrease From Baseline
NCT00098306 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL or With at Least 1.0 log10 Decrease From Baseline
NCT00098306 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
NCT00098306 (18) [back to overview]	Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels
NCT00098306 (18) [back to overview]	Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48
NCT00098306 (18) [back to overview]	Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline
NCT00098306 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
NCT00098722 (18) [back to overview]	Change From Baseline in CD8 Cell Count at Week 24 and 48
NCT00098722 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
NCT00098722 (18) [back to overview]	Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels
NCT00098722 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline
NCT00098722 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
NCT00098722 (18) [back to overview]	Number of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening
NCT00098722 (18) [back to overview]	Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48
NCT00098722 (18) [back to overview]	Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24
NCT00098722 (18) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
NCT00098722 (18) [back to overview]	Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24
NCT00098722 (18) [back to overview]	Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline
NCT00098722 (18) [back to overview]	Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening
NCT00098722 (18) [back to overview]	Change From Baseline in CD4 Cell Count at Week 24 and 48
NCT00098722 (18) [back to overview]	Time to Virological Failure
NCT00098722 (18) [back to overview]	Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline
NCT00098722 (18) [back to overview]	Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48
NCT00098722 (18) [back to overview]	Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24
NCT00098722 (18) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline
NCT00098748 (15) [back to overview]	Number of Subjects With HIV-1 RNA Levels < 400 Copies/mL or at Least 0.5 Log 10-transformed Decrease From Baseline in HIV-1 RNA Levels
NCT00098748 (15) [back to overview]	Number of Subjects With HIV-1 RNA Levels < 50 Copies/mL
NCT00098748 (15) [back to overview]	Number of Subjects With HIV-1 RNA Levels < 400 Copies/mL or at Least 1.0 Log 10-transformed Decrease From Baseline in HIV-1 RNA Levels
NCT00098748 (15) [back to overview]	Change From Baseline in CD8 Cell Count
NCT00098748 (15) [back to overview]	Number of Subjects With Treatment Failure at Week 24 by Overall Susceptibility Score (OSS) at Screening
NCT00098748 (15) [back to overview]	Time (50% Quartile Point Estimate) to Virologic Failure
NCT00098748 (15) [back to overview]	Number of Subjects With Treatment Failure at Week 48 by Overall Susceptibility Score (OSS) at Screening
NCT00098748 (15) [back to overview]	Number of Subjects With HIV-1 RNA Levels < 400 Copies/mL
NCT00098748 (15) [back to overview]	Number of Subjects With Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Illnesses (Analysis at Week 48)
NCT00098748 (15) [back to overview]	Number of Subjects With Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Illnesses (Analysis at Week 24)
NCT00098748 (15) [back to overview]	Number of Subjects Per Tropism Status at Screening and Time of Treatment Failure (Analysis at Week 48)
NCT00098748 (15) [back to overview]	Number of Subjects Per Tropism Status at Screening and at the Time of Treatment Failure (Analysis at Week 24)
NCT00098748 (15) [back to overview]	Change From Baseline in Time Averaged Difference (TAD) in log10 HIV-1 RNA
NCT00098748 (15) [back to overview]	Change From Baseline in Human Immunodeficiency Virus (HIV-1) Viral Load (Ribonucleic Acid [RNA])
NCT00098748 (15) [back to overview]	Change From Baseline in CD4 Cell Count
NCT00426660 (21) [back to overview]	Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by Gender
NCT00426660 (21) [back to overview]	Percentage of Participants With ≥0.5 log10 Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)
NCT00426660 (21) [back to overview]	Change From Baseline in CD8 Cell Count
NCT00426660 (21) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL
NCT00426660 (21) [back to overview]	Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL
NCT00426660 (21) [back to overview]	Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities
NCT00426660 (21) [back to overview]	Percentage of Participants With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure
NCT00426660 (21) [back to overview]	Change From Baseline in CD8 Cell Count Percent
NCT00426660 (21) [back to overview]	Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status
NCT00426660 (21) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Race
NCT00426660 (21) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Age
NCT00426660 (21) [back to overview]	Percentage of Participants With ≥1.0 log10 Reduction From Baseline in HIV 1 RNA
NCT00426660 (21) [back to overview]	Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses
NCT00426660 (21) [back to overview]	Median Time to Virologic Failure
NCT00426660 (21) [back to overview]	Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)
NCT00426660 (21) [back to overview]	Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau
NCT00426660 (21) [back to overview]	Change From Baseline in CD4 Cell Count
NCT00426660 (21) [back to overview]	Change From Baseline in CD4 Cell Count Percent
NCT00426660 (21) [back to overview]	Percentage of Participants With Changes in HIV-1 RNA Level in Participants Meeting the Definition of Virologic Failure
NCT00426660 (21) [back to overview]	Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)
NCT00426660 (21) [back to overview]	Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities
NCT00427934 (25) [back to overview]	Number of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline
NCT00427934 (25) [back to overview]	Number of Subjects With Withdrawal From Study Due to Lack of Efficacy
NCT00427934 (25) [back to overview]	Survival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.
NCT00427934 (25) [back to overview]	Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).
NCT00427934 (25) [back to overview]	Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).
NCT00427934 (25) [back to overview]	American College of Rheumatology (ACR) 20% Responders at Week 12
NCT00427934 (25) [back to overview]	ACR 70% Responders at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in CRP at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Mean Heart Rate
NCT00427934 (25) [back to overview]	Change From Baseline in Mean Orthostatic Blood Pressure (BP)
NCT00427934 (25) [back to overview]	Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1
NCT00427934 (25) [back to overview]	Change From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	Maximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1
NCT00427934 (25) [back to overview]	Number of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline
NCT00427934 (25) [back to overview]	Time for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1
NCT00427934 (25) [back to overview]	ACR 50% Responders at Weeks 1, 2, 4, 8, and 12
NCT00427934 (25) [back to overview]	ACR 20% Responders at Weeks 1, 2, 4, and 8
NCT00478231 (16) [back to overview]	Time to Virologic Failure (VF)
NCT00478231 (16) [back to overview]	Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
NCT00478231 (16) [back to overview]	Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
NCT00478231 (16) [back to overview]	Change From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
NCT00478231 (16) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
NCT00478231 (16) [back to overview]	Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
NCT00478231 (16) [back to overview]	Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status
NCT00478231 (16) [back to overview]	Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections
NCT00478231 (16) [back to overview]	Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities
NCT00478231 (16) [back to overview]	Number of Participants With Genotype Resistance
NCT00478231 (16) [back to overview]	Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00478231 (16) [back to overview]	Number of Participants With Laboratory Test Abnormalities
NCT00478231 (16) [back to overview]	Number of Participants With Treatment Emergent Malignancies
NCT00478231 (16) [back to overview]	Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification
NCT00478231 (16) [back to overview]	Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)
NCT00478231 (16) [back to overview]	Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA
NCT00525733 (1) [back to overview]	The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study Hypothesis is That New Treatment is Better Than the Control Group.
NCT00537394 (15) [back to overview]	Time From Treatment Dispensation to First Study ARV Modification (Excluding NRTIs, if Applicable)
NCT00537394 (15) [back to overview]	Time From Treatment Dispensation to Serious Non-AIDS-defining Events
NCT00537394 (15) [back to overview]	Change in CD4 Count From Baseline
NCT00537394 (15) [back to overview]	Change in Plasma HIV-1 Viral Load From Baseline to Week 1
NCT00537394 (15) [back to overview]	Number of Participants With Change in Virus Co-receptor Tropism Among Those With R5-only Tropic Virus at Study Entry
NCT00537394 (15) [back to overview]	Participants With Newly Acquired HIV Drug Resistance Between Study Entry and Confirmed Virologic Failure
NCT00537394 (15) [back to overview]	Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment
NCT00537394 (15) [back to overview]	Change in Cardiovascular Risk Score From Baseline
NCT00537394 (15) [back to overview]	Change in Fasting Non-HDL Cholesterol From Baseline
NCT00537394 (15) [back to overview]	Change in Summarized Quality of Life Score
NCT00537394 (15) [back to overview]	Number of Participants Self-reporting Non-adherence to Assigned Study ARVS (Excluding NRTIs, if Applicable)
NCT00537394 (15) [back to overview]	Number of Participants With Plasma HIV-1 Viral Load < 50 Copies/ml
NCT00537394 (15) [back to overview]	Time From Randomization to Confirmed Virological Failure
NCT00537394 (15) [back to overview]	Time From Randomization to Discontinuation of Randomized NRTI Component of Study Treatment
NCT00537394 (15) [back to overview]	Time From Treatment Dispensation to First Grade 3 or Higher (and at Least One Grade Higher Than Baseline) Signs/Symptom or Laboratory Abnormality
NCT00624195 (1) [back to overview]	Neuropsychological Performance Change
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections
NCT00665561 (15) [back to overview]	Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'
NCT00665561 (15) [back to overview]	Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'
NCT00665561 (15) [back to overview]	Adjusted Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause
NCT00665561 (15) [back to overview]	Adjusted Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C Aids-Defining Opportunistic Infections
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Liver Failure
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis
NCT00665561 (15) [back to overview]	Percentage of Participants With All-Cause Mortality
NCT00665561 (15) [back to overview]	Adjusted Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)
NCT00665561 (15) [back to overview]	Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)
NCT00666705 (6) [back to overview]	Maraviroc Pharmacokinetic (PK) Parameter: 12-Hour Trough Concentration (C12)
NCT00666705 (6) [back to overview]	Maraviroc Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax)
NCT00666705 (6) [back to overview]	Raltegravir Pharmacokinetics (PK) Parameter: 12-Hour Trough Concentration (C12)
NCT00666705 (6) [back to overview]	Raltegravir Pharmacokinetics (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
NCT00666705 (6) [back to overview]	Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
NCT00666705 (6) [back to overview]	Raltegravir Pharmacokinetics (PK) Parameter: Maximum Concentration (Cmax)
NCT00709111 (35) [back to overview]	Change in IL-6, MCP-1, MCP-2, and Plasma CD40L
NCT00709111 (35) [back to overview]	Change in IL-6, MCP-1, MCP-2, and Plasma CD40L
NCT00709111 (35) [back to overview]	Change in Intercellular Cell Adhesion Molecule (ICAM)-1, Plasma P-selectin, Soluble TNFRII (sTNFRII), and Matrix Metalloproteinase (MMP)-9
NCT00709111 (35) [back to overview]	Change in Interleukin (IL)-6, Monocyte Chemoattractant Protein (MCP)-1, MCP-2, and Plasma CD40 Ligand (CD40L)
NCT00709111 (35) [back to overview]	Change in Percentage of CD4+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Change in Percentage of CD4+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Change in Percentage of CD4+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Change in Percentage of CD8+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Change in Percentage of CD8+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Change in Percentage of CD8+ T-cells That Are: naïve (%CD45RA+CCR7+), Central Memory (%CD45RA-CCR7+), Effector Memory (%CD45RA-CCR7-), Effector (%CD45RA+CCR7-), %HLA-DR+CD38+, %CD38+, %Ki67+, %caspase3+, %Bcl-2-, and %CD57+
NCT00709111 (35) [back to overview]	Drug Adherence Assessed as Number of Missed Doses Over a 4-day Recall
NCT00709111 (35) [back to overview]	Number of Subjects Who Experience a Grade 2, 3 or 4 Signs and Symptoms, Grade 3 or 4 Laboratory Abnormalities, or Death.
NCT00709111 (35) [back to overview]	Proportion of Participants With Detectable HIV-1 Viremia as Measured by Single Copy Assay (SCA)
NCT00709111 (35) [back to overview]	Change in ICAM-1, Plasma P-selectin, sTNFRII, and MMP-9
NCT00709111 (35) [back to overview]	Change in D-dimer
NCT00709111 (35) [back to overview]	Change From Within-subject Pre-treatment CD4+ T-cell Count Slopes to Corresponding Within-subject CD4+ T-cell Count Slopes From Baseline Through Week 24
NCT00709111 (35) [back to overview]	Change in CD4 Percentage
NCT00709111 (35) [back to overview]	Change in CD4 Percentage
NCT00709111 (35) [back to overview]	Change in CD4 Percentage
NCT00709111 (35) [back to overview]	Change in ICAM-1, Plasma P-selectin, sTNFRII, and MMP-9
NCT00709111 (35) [back to overview]	Change in CD4+ T-cell Count
NCT00709111 (35) [back to overview]	Change in CD4+ T-cell Count
NCT00709111 (35) [back to overview]	Change in CD4+ T-cell Count
NCT00709111 (35) [back to overview]	Change in D-dimer
NCT00709111 (35) [back to overview]	Change in D-dimer
NCT00709111 (35) [back to overview]	Change in High Sensitivity C-reactive Protein (Hs-CRP)
NCT00709111 (35) [back to overview]	Change in Hs-CRP
NCT00709111 (35) [back to overview]	Change From Within-subject Pre-treatment CD4 Percentage Slopes to Corresponding Within-subject CD4 Percentage Slopes From Baseline Through Week 24
NCT00709111 (35) [back to overview]	Change in Hs-CRP
NCT00709111 (35) [back to overview]	Change in Soluble CD14
NCT00709111 (35) [back to overview]	Change in Soluble CD14
NCT00709111 (35) [back to overview]	Change in Soluble CD14
NCT00709111 (35) [back to overview]	Proportion of Participants Achieving a 50-cell Increase in CD4+ T-cell Count
NCT00709111 (35) [back to overview]	Within-subject CD4 Percentage Slopes
NCT00709111 (35) [back to overview]	Within-subject CD4+ T-cell Count Slopes
NCT00717067 (13) [back to overview]	Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function
NCT00717067 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT00717067 (13) [back to overview]	Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD
NCT00717067 (13) [back to overview]	Half-life (t1/2)
NCT00717067 (13) [back to overview]	Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae
NCT00717067 (13) [back to overview]	AUCtau
NCT00717067 (13) [back to overview]	Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum EGC QTC, QTCB and QTCF Intervals
NCT00717067 (13) [back to overview]	Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum Increase and Decrease in Supine Blood Pressure
NCT00717067 (13) [back to overview]	Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)
NCT00717067 (13) [back to overview]	Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Pulse Rate < 40 and > 120 Beats Per Minute
NCT00717067 (13) [back to overview]	Plasma Protein Binding
NCT00717067 (13) [back to overview]	Time of First Occurrence (Tmax)
NCT00717067 (13) [back to overview]	Area Under the Time Curve From 0 to Infinity (AUCinf)
NCT00735072 (5) [back to overview]	Change in CD4+ T Cell Count
NCT00735072 (5) [back to overview]	Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells)
NCT00735072 (5) [back to overview]	Change in Ultra-sensitive Plasma HIV RNA Level (Single Copy/ml Assay)
NCT00735072 (5) [back to overview]	Change in Gut-associated Lymphoid Tissue HIV RNA Level (UCSF Site Only)
NCT00735072 (5) [back to overview]	Change in Brachial Artery Flow-mediated Dilatation (UCSF Site Only)
NCT00764465 (5) [back to overview]	AUC: Steady-state Plasma MVC PK Following Administration of RTV
NCT00764465 (5) [back to overview]	AUC: Steady-state Plasma Amprenavir (APV) Pharmacokinetics ( PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or FPV 1400mg/RTV 100mg QD With and Without Concurrent (Maraviroc) MVC 300mg BID.
NCT00764465 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event
NCT00764465 (5) [back to overview]	Cmin/Cmax: Steady-state Plasma Amprenavir (APV) Pharmacokinetics ( PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or FPV 1400mg/RTV 100mg QD With and Without Concurrent (Maraviroc) MVC 300mg BID.
NCT00764465 (5) [back to overview]	Cmin/Cmax: Steady-state Plasma MVC PK Following Administration of RTV
NCT00791700 (19) [back to overview]	Percentage of Participants With HIV-1 RNA Levels < 48 Copies/mL at Weeks 24 and 48 Using MD=F Approach
NCT00791700 (19) [back to overview]	Percentage of Participants With HIV-1 RNA Levels <400 Copies/mL at Weeks 24 and 48 Using Missing, Discontinuation = Failure (MD=F)Approach
NCT00791700 (19) [back to overview]	Percentage of Participants With Optimized Background Treatment Susceptibility Scores
NCT00791700 (19) [back to overview]	Pharmacokinetic(PK): Maraviroc PK Parameter, Average Plasma Concentration (Cavg), Trough Concentration(Cmin), Maximum Plasma Concentration (Cmax)
NCT00791700 (19) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax)
NCT00791700 (19) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL and <48 Copies/mL Using the Time to Loss of Virologic Response Algorithm (TLOVR) at Week 48
NCT00791700 (19) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F) Approach
NCT00791700 (19) [back to overview]	Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug
NCT00791700 (19) [back to overview]	Area Under the Curve at Steady State (AUCtau)
NCT00791700 (19) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 24 and 48
NCT00791700 (19) [back to overview]	Change From Baseline in HIV-1 RNA (Log10 Copies/mL)
NCT00791700 (19) [back to overview]	Change From Baseline in HIV-1 RNA (Original)
NCT00791700 (19) [back to overview]	Change From Baseline in Percentage (%) of CD4+ Cells at Weeks 24 and 48
NCT00791700 (19) [back to overview]	Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events(AEs) (All Causality)
NCT00791700 (19) [back to overview]	Number of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) and Protease Inhibitor (PI) Resistance Associated Mutations (RAMs) Between Screening and On-Treatment Confirmed PDVF
NCT00791700 (19) [back to overview]	Number of Participants With Protocol Defined Virologic Failure
NCT00791700 (19) [back to overview]	Number of Participants With Viral Tropism Between Screening and Confirmed Protocol Defined Virologic Failure (PDVF) Prior to Week 48
NCT00791700 (19) [back to overview]	Percentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration From Baseline to Week 24 and Week 48
NCT00791700 (19) [back to overview]	Percentage of Participants With HIV-1 RNA <48 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F)Approach
NCT00827112 (16) [back to overview]	HIV-1 RNA Levels at Baseline
NCT00827112 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Maraviroc
NCT00827112 (16) [back to overview]	Number of Participants With Phenotypic Resistance
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Time to Loss of Virological Response (TLOVR)
NCT00827112 (16) [back to overview]	Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
NCT00827112 (16) [back to overview]	Time-Averaged Difference (TAD) in log10 Viral Load
NCT00827112 (16) [back to overview]	Average Observed Plasma Concentration (Cavg) of Maraviroc
NCT00827112 (16) [back to overview]	Number of Participants With Genotypic Resistance
NCT00827112 (16) [back to overview]	Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Minimum Observed Plasma Concentration (Cmin) of Maraviroc
NCT00827112 (16) [back to overview]	Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14
NCT00844519 (1) [back to overview]	Percent Change in FMD
NCT00850395 (13) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 6
NCT00850395 (13) [back to overview]	Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 3
NCT00850395 (13) [back to overview]	Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 6
NCT00850395 (13) [back to overview]	Number of Participants With Human Immunodeficiency Virus (HIV) Response
NCT00850395 (13) [back to overview]	Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Overall Score at Months 6 and 12
NCT00850395 (13) [back to overview]	Number of Participants Taking Concomitant Therapy
NCT00850395 (13) [back to overview]	Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 12
NCT00850395 (13) [back to overview]	Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 3
NCT00850395 (13) [back to overview]	Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 6
NCT00850395 (13) [back to overview]	Physician's Assessment of Efficacy
NCT00850395 (13) [back to overview]	Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 12
NCT00850395 (13) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 12
NCT00850395 (13) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 3
NCT00853840 (5) [back to overview]	Postural Changes in Pulse Rate
NCT00853840 (5) [back to overview]	Number of Subjects With Postural Hypotension
NCT00853840 (5) [back to overview]	Standing and Supine Systolic and Diastolic Blood Pressure (BP)
NCT00853840 (5) [back to overview]	Standing and Supine Pulse Rate
NCT00853840 (5) [back to overview]	Postural Changes in Systolic and Diastolic Blood Pressure
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Mean Daily Dose of Celsentri
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Inpatient or Outpatient Status
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor HIV Infection Duration
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Gender
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Ethnicity
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Centers for Disease Control and Prevention (CDC) Classification
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor as Per Presence or Absence of Concomitant Therapies
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Age
NCT00864474 (35) [back to overview]	Mean Number of Plasma Human Immuno-Deficiency Virus-Ribosomal Ribonucleic Acid (HIV-RNA) Copies: Factor The Presence or Absence of Comorbidities
NCT00864474 (35) [back to overview]	Mean Number of Plasma Human Immuno-Deficiency Virus-Ribosomal Ribonucleic Acid (HIV-RNA) Copies: Factor Gender
NCT00864474 (35) [back to overview]	Mean Number of Plasma HIV-RNA Copies: Factor The Presence or Absence of Use of Cytochrome P450 3A4 (CYP3A4) Enzyme Inducer Taken Along With Celsentri
NCT00864474 (35) [back to overview]	Mean Number of Plasma HIV-RNA Copies: Factor The Presence or Absence of History of Therapies for HIV Infection
NCT00864474 (35) [back to overview]	Mean Number of Plasma HIV-RNA Copies: Factor The Centers for Disease Control and Prevention (CDC) Classification
NCT00864474 (35) [back to overview]	Mean Number of Plasma HIV-RNA Copies for Participants Who Took Concomitant Therapies Along With Celsentri
NCT00864474 (35) [back to overview]	Mean Number of CD4+ Lymphocyte: Factor The Presence or Absence of Use of Cytochrome P450 3A4 (CYP3A4) Enzyme Inducer Taken Along With Celsentri
NCT00864474 (35) [back to overview]	Mean Number of CD4+ Lymphocyte Counts: Fcator The Presence or Absence of Comorbidities
NCT00864474 (35) [back to overview]	Mean Number of CD4+ Lymphocyte Counts: Factor The Centers for Disease Control and Prevention (CDC) Classification
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Hemophilia
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Comorbidities
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Allergies
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Number of Concomitant Anti-HIV Drugs Use
NCT00864474 (35) [back to overview]	Mean Number of CD4+ Lymphocyte Counts: Factor Presence or Absence of History of Therapies for HIV Infection
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs)
NCT00864474 (35) [back to overview]	Number of Participants With Unknown Adverse Drug Reactions (ADRs)
NCT00864474 (35) [back to overview]	Number of Participants With Tropism Switch From CCR5- to CXCR4-Tropic Variants
NCT00864474 (35) [back to overview]	Number of Adverse Drug Reactions (ADRs) Considered to Have Occurred Due to Effect of Celsentri on Immune Function
NCT00864474 (35) [back to overview]	Number of Adverse Drug Reactions (ADRs) Considered to Have Occurred Due to Effect of Celsentri on Hepatic Function
NCT00864474 (35) [back to overview]	Number of Adverse Drug Reactions (ADRs) Considered to Have Occurred Due to Effect of Celsentri on Cardiovascular Effects
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Mean Total Dose of Celsentri
NCT00864474 (35) [back to overview]	Mean Number of Cluster of Differentiation of More Than 4 (CD4+) Lymphocyte Count: Factor Gender
NCT00864474 (35) [back to overview]	Primary: Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of History of Therapies for Human Immuno-Deficiency Virus (HIV) Infection
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Total Number of Days of Administration of Celsentri
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Use of Cytochrome P450 3A4 (CYP3A4) Enzyme Inducer Taken Along With Celsentri
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Renal Impairment
NCT00864474 (35) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs): Factor Presence or Absence of Hepatic Impairment
NCT00870363 (4) [back to overview]	Trough Plasma and Tissue Drug Levels in Volunteers at the Time of the Upper Endoscopy
NCT00870363 (4) [back to overview]	Change in HIV DNA Per 10^6 Cells in Duodenal Tissue Versus PBMC by Drug Regimen Received
NCT00870363 (4) [back to overview]	Changes in CD4+ T-cell Numbers by Treatment Regimen
NCT00870363 (4) [back to overview]	Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen
NCT00925756 (3) [back to overview]	Change in CD4+/CD8+ T-cell Immune Activation, Maturation, Regulatory and Apoptosis Markers at Baseline and Weeks 4 and 24.
NCT00925756 (3) [back to overview]	Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24.
NCT00925756 (3) [back to overview]	CD4+ T-cell Absolute Count and Percentage at Baseline, Weeks 4 and 24.
NCT00948753 (6) [back to overview]	Rate of Early Mortality After Transplant
NCT00948753 (6) [back to overview]	Number of Patients Treated With Maraviroc During SCT That Develop Chronic GVHD
NCT00948753 (6) [back to overview]	Number of Participants Who Relapsed During Study Period
NCT00948753 (6) [back to overview]	Efficacy of Maraviroc
NCT00948753 (6) [back to overview]	Pharmacokinetic Profile of Maraviroc in Patients Undergoing Nonmyeloablative Allogeneic SCT
NCT00948753 (6) [back to overview]	Safety of Maraviroc
NCT00976404 (5) [back to overview]	Change From Baseline in HIV DNA in Rectal Tissue at Week 56
NCT00976404 (5) [back to overview]	Serious Adverse Events Attributed to Study Treatments
NCT00976404 (5) [back to overview]	HIV Specific T-cell Response to Env
NCT00976404 (5) [back to overview]	Change From Baseline in HIV DNA in PBMCs at Week 56
NCT00976404 (5) [back to overview]	Change From Baseline in CD4+ T Cell Count at Week 56
NCT00982878 (2) [back to overview]	Number of Participants With Adverse Events
NCT00982878 (2) [back to overview]	CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS)
NCT00987948 (2) [back to overview]	Change From Baseline to 24 Weeks in Neuropsychological Performance As Measured by Age- and Education-Adjusted Z-Scores
NCT00987948 (2) [back to overview]	Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells
NCT00993148 (9) [back to overview]	Drug Adherence, Number of Participants With Missed Doses
NCT00993148 (9) [back to overview]	Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES
NCT00993148 (9) [back to overview]	Median CD4 Count Change From Baseline
NCT00993148 (9) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA >50
NCT00993148 (9) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA >50 Copies/mL
NCT00993148 (9) [back to overview]	Percentage of Participants With Virologic Failure or Off Study Treatment Regimen
NCT00993148 (9) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA >50 Copies/mL
NCT00993148 (9) [back to overview]	Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher
NCT00993148 (9) [back to overview]	Trough Concentrations (Ctrough) of Maraviroc
NCT01068873 (1) [back to overview]	Number of Participants With HIV RNA < 50 and <400 Copies/ml.
NCT01154673 (1) [back to overview]	Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo in Addition to Standard HAART.
NCT01204905 (2) [back to overview]	Viral Load
NCT01204905 (2) [back to overview]	Viral Suppression
NCT01275625 (11) [back to overview]	Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Load <50 Copies/Milliliter (mL) at 48 Weeks.
NCT01275625 (11) [back to overview]	Number of Participants With Genotypic Resistance.
NCT01275625 (11) [back to overview]	Number of Participants With HIV-1 RNA Tropism Status Using Genotyping Assay at Screening and at the Time of Virologic Failure.
NCT01275625 (11) [back to overview]	Virologic Response: Percentage of Participants With Plasma HIV-1 RNA Load < 400 Copies/mL at Post-baseline Visits.
NCT01275625 (11) [back to overview]	Virologic Response: Percentage of Participants With Plasma HIV-1 RNA Load <50 Copies/mL at Post-baseline Visits.
NCT01275625 (11) [back to overview]	Virologic Response: Rate of Virologic Failure at Week 48.
NCT01275625 (11) [back to overview]	Immunological Response at Week 48: Absolute Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)
NCT01275625 (11) [back to overview]	Immunological Response at Week 48: Absolute Change From Baseline in Absolute Cluster of Differentiation 8 (CD8)
NCT01275625 (11) [back to overview]	Immunological Response at Week 48: Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)/ Cluster of Differentiation 8 (CD8) Ratio.
NCT01275625 (11) [back to overview]	Immunological Response at Week 48: Percentage Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)
NCT01275625 (11) [back to overview]	Immunological Response at Week 48: Percentage Change From Baseline in Absolute Cluster of Differentiation 8 (CD8)
NCT01276236 (7) [back to overview]	Change in Edema Grade
NCT01276236 (7) [back to overview]	Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area
NCT01276236 (7) [back to overview]	Percent Change in CCR5 Levels on CD4+ T-Cells
NCT01276236 (7) [back to overview]	Percent Change in CCR5 Levels on CD8+ T-cells
NCT01276236 (7) [back to overview]	Percent Change in CD69 Expression in a Subset of Double Negative DR-CD38 Negative (DR-CD38-) T-cells
NCT01276236 (7) [back to overview]	Percent Change in CD69 Expression in a Subset of Double Negative DR-CD38 Positive (DR-CD38+) T-cells
NCT01276236 (7) [back to overview]	Percent Change in KS Total Surface Area
NCT01327547 (21) [back to overview]	Mean Change From Baseline in the Hepatic Elastography (FibroscanTM) at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Plasma Hepatitis B Virus (HBV) DNA at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Markers of Immune Activation: Transforming Growth Factor-beta (TGF Beta) - Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Markers of Immune Activation: D Dimer - Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Markers of Immune Activation: C-reactive Protein (CRP) - Week 48, 96 and 144.
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Log10 Plasma Hepatitis C Virus (HCV) RNA at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in Enhanced Liver Fibrosis (ELF) Test at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Mean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144
NCT01327547 (21) [back to overview]	Change From Baseline in Fibrosis Score (Ishak) in Liver Biopsy Samples at Week 144
NCT01327547 (21) [back to overview]	Absolute Fibrosis Score (Ishak) in Liver Biopsy Samples at Baseline and at Week 144
NCT01327547 (21) [back to overview]	Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L
NCT01327547 (21) [back to overview]	Mean Change From Baseline in CD4+ and CD8+ Cell Counts at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Time to Development of Grade 3 and Grade 4 ALT Abnormalities
NCT01327547 (21) [back to overview]	Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48
NCT01327547 (21) [back to overview]	Number of Participants With Hy's Law Abnormalities Through Week 144
NCT01327547 (21) [back to overview]	Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48
NCT01327547 (21) [back to overview]	Summary of Estimated Maraviroc PK Parameters
NCT01327547 (21) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Concentration <40 Copies/mL at Week 48, 96 and 144
NCT01327547 (21) [back to overview]	Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144
NCT01327547 (21) [back to overview]	Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Associated With a Change From Baseline ALT >100 IU/L
NCT01327547 (21) [back to overview]	Percentage of Participants Who Were Hospitalized Due to Hepatic Disease Through Week 144
NCT01345630 (25) [back to overview]	Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
NCT01345630 (25) [back to overview]	Severity of Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Tropism Change Between Screening or Baseline and PDTF
NCT01345630 (25) [back to overview]	Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
NCT01345630 (25) [back to overview]	Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
NCT01345630 (25) [back to overview]	Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
NCT01345630 (25) [back to overview]	Frequency of Adverse Events (AE).
NCT01345630 (25) [back to overview]	Number of Participants Who Discontinued Due to AEs
NCT01345630 (25) [back to overview]	Number of Participants With Grade 3 or 4 AEs
NCT01345630 (25) [back to overview]	Number of Participants With Treatment-emergent Serious Adverse Events
NCT01345630 (25) [back to overview]	Number of Treatment-related AEs
NCT01345630 (25) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
NCT01345630 (25) [back to overview]	The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
NCT01345630 (25) [back to overview]	Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
NCT01345630 (25) [back to overview]	Number of Participants With Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
NCT01348763 (2) [back to overview]	The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day
NCT01348763 (2) [back to overview]	Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests
NCT01400412 (20) [back to overview]	Change in Level of IP-10 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+/CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 24
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Lumbar Spine Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	CD8+ T-cell Change From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of RANKL+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of D-dimer From Baseline
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD4+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of IL-6 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of sCD14 From Baseline
NCT01400412 (20) [back to overview]	Change in Levels of sCD163 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Number of Participants Who Developed Grade 3 or 4 Primary Adverse Events
NCT01400412 (20) [back to overview]	Number of Participants Who Died During the Study
NCT01400412 (20) [back to overview]	Cumulative Probability of Virologic Failure by Week 48
NCT01400412 (20) [back to overview]	Number of Participants Who Experienced Bone Fractures
NCT01400412 (20) [back to overview]	Percent Change From Baseline in Total Hip Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD8+ T Cells From Baseline to Week 48
NCT01449006 (4) [back to overview]	Change in MRS Cerebral Metabolite Ratios in Frontal White Matter
NCT01449006 (4) [back to overview]	Change in MRS Cerebral Metabolite Ratios in Basal Ganglia
NCT01449006 (4) [back to overview]	Change in CSF Neopterin Concentration
NCT01449006 (4) [back to overview]	Change in Neurocognitive Functioning
NCT01505114 (1) [back to overview]	Occurrence of Grade 3 or Higher Adverse Events (AEs)
NCT01785810 (1) [back to overview]	Day +180 Rate of Grade II-IV Acute GVHD
NCT01894776 (3) [back to overview]	Safety/Tolerability of the Treatments
NCT01894776 (3) [back to overview]	Pharmacokinetics of Maraviroc and Rifabutin AUC 0-12/24
NCT01894776 (3) [back to overview]	Maraviroc and Rifabutin C12/C24/Cmax PK Concentrations in Plasma.
NCT01896921 (3) [back to overview]	Number of Participants With Adverse Events
NCT01896921 (3) [back to overview]	Number of Patients Virologically Suppressed (HIV RNA <50 Copies/ml) at 48 Weeks.
NCT01896921 (3) [back to overview]	Number of Patients Who Are Virologically Suppressed (HIV RNA < 50 Copies/ml)
NCT02167451 (12) [back to overview]	Toxicities
NCT02167451 (12) [back to overview]	Area Under The Concentration-Time Curve (AUC) of Maraviroc
NCT02167451 (12) [back to overview]	Infectious Complications
NCT02167451 (12) [back to overview]	Area Under The Concentration-Time Curve (AUC) of Maraviroc
NCT02167451 (12) [back to overview]	Feasibility of Maraviroc
NCT02167451 (12) [back to overview]	Graft Failure
NCT02167451 (12) [back to overview]	GVHD Incidence
NCT02167451 (12) [back to overview]	Incidence of Visceral GVHD
NCT02167451 (12) [back to overview]	Overall Survival
NCT02167451 (12) [back to overview]	Primary Disease Relapse
NCT02167451 (12) [back to overview]	Time to Neutrophil
NCT02167451 (12) [back to overview]	Time to Platelet Engraftment
NCT02208037 (13) [back to overview]	Percentage of Participants With Neutrophil Recovery
NCT02208037 (13) [back to overview]	Percentage of Participants With Chronic GVHD
NCT02208037 (13) [back to overview]	Percentage of Participants With Chronic GVHD Requiring Immunosupressive Therapy
NCT02208037 (13) [back to overview]	Percentage of Participants With Disease Relapse or Progression
NCT02208037 (13) [back to overview]	Percentage of Participants With Grade III-IV Acute GVHD
NCT02208037 (13) [back to overview]	Percentage of Participants With GVHD-free Survival
NCT02208037 (13) [back to overview]	Percentage of Participants With Grade II-IV Acute GVHD
NCT02208037 (13) [back to overview]	Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS)
NCT02208037 (13) [back to overview]	Percentage of Participants With Overall Survival
NCT02208037 (13) [back to overview]	Percentage of Participants With Transplant-Related Mortality (TRM)
NCT02208037 (13) [back to overview]	Percentage of Participants With Platelet Recovery
NCT02208037 (13) [back to overview]	Donor Cell Engraftment
NCT02208037 (13) [back to overview]	Percentage of Participants With Disease-free Survival
NCT02333045 (1) [back to overview]	Count of Total Cells Obtained From Cervicovaginal Lavage Samples
NCT02519777 (17) [back to overview]	Number of Participants With Treatment Related Adverse Events (AEs)
NCT02519777 (17) [back to overview]	CD8+ T-cell Counts
NCT02519777 (17) [back to overview]	Change in CD4+ T-cell Count
NCT02519777 (17) [back to overview]	Change in CD8+ T-cell Count
NCT02519777 (17) [back to overview]	Change in Functional Status Scores
NCT02519777 (17) [back to overview]	Change in Normalized Composite Neurocognitive Test Score at Weeks 24, 72, and 96 From Baseline
NCT02519777 (17) [back to overview]	Number of Participants With Plasma HIV-1 RNA Greater Than or Equal to 50 Copies/mL
NCT02519777 (17) [back to overview]	CD4+ T-cell Counts
NCT02519777 (17) [back to overview]	Change in Log10 IP-10 in CSF at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 MIP-1 Beta in Cerebrospinal Fluid (CSF) at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 MIP-1 Beta in Plasma at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 Neopterin in CSF at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 NFL in CSF at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 sCD14 in Plasma at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 sTNFr-II in Plasma at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Log10 VCAM in Plasma at Week 48 From Baseline
NCT02519777 (17) [back to overview]	Change in Normalized Composite Neurocognitive Test Score at Week 48 From Baseline
NCT02625207 (24) [back to overview]	Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose
NCT02625207 (24) [back to overview]	Part 2: Number of Participants With Laboratory Abnormalities
NCT02625207 (24) [back to overview]	Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities
NCT02625207 (24) [back to overview]	Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
NCT02625207 (24) [back to overview]	Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
NCT02625207 (24) [back to overview]	Part 2: Average Plasma Concentration (Cavg) of Maraviroc
NCT02625207 (24) [back to overview]	Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose
NCT02625207 (24) [back to overview]	Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
NCT02625207 (24) [back to overview]	Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities
NCT02625207 (24) [back to overview]	Part 1: Average Plasma Concentration (Cavg) of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc
NCT02625207 (24) [back to overview]	Part 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02625207 (24) [back to overview]	Part 1: Number of Participants With Laboratory Abnormalities
NCT02625207 (24) [back to overview]	Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose
NCT02625207 (24) [back to overview]	Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02625207 (24) [back to overview]	Part 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)
NCT02625207 (24) [back to overview]	Part 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc
NCT02625207 (24) [back to overview]	Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc
NCT02625207 (24) [back to overview]	Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
NCT02741323 (29) [back to overview]	Tissue Common Rejection Module (tCRM) Score Using the 11-gene tCRM Module on FFPE Biopsy Shaves
NCT02741323 (29) [back to overview]	Trough Levels of CCR5 Blockade (Maraviroc)
NCT02741323 (29) [back to overview]	Urine Common Rejection Module (uCRM) Score Using the 11-gene uCRM Module on Urine Cell Pellets
NCT02741323 (29) [back to overview]	Urine Common Rejection Module (uCRM) Score Using the 11-gene uCRM Module on Urine Cell Pellets
NCT02741323 (29) [back to overview]	AUC of CCR5 Blockade (Maraviroc)
NCT02741323 (29) [back to overview]	Incidence/Proportion of Participants With HIV Infection in the Renal Allograft
NCT02741323 (29) [back to overview]	Calcineurin Inhibitor (Tacrolimus) AUC for Participants on Maraviroc Versus Placebo
NCT02741323 (29) [back to overview]	Calcineurin Inhibitor (Tacrolimus) Trough Levels for Participants on Maraviroc Versus Placebo
NCT02741323 (29) [back to overview]	Cumulative Incidence of Graft Loss, Toxicities ≥ Grade 3 Per the DAIDS Toxicity Table and/or Permanent Treatment Discontinuation
NCT02741323 (29) [back to overview]	Cumulative Incidence/Proportion of Acute Cellular Rejection Grade Equal to or Greater Than 1A During the Entire Study Follow-up
NCT02741323 (29) [back to overview]	Cumulative Incidence/Proportion of Biopsy Proven Acute Rejection Within 1 Year Post Transplant
NCT02741323 (29) [back to overview]	HIV DNA in Peripheral Blood CD4+ T Cells at Week 52
NCT02741323 (29) [back to overview]	HIV RNA in Peripheral Blood CD4+ T Cells at Week 52.
NCT02741323 (29) [back to overview]	Incidence of All Adverse Events (AEs) Greater Than or Equal to Grade 3 at Year 1
NCT02741323 (29) [back to overview]	Incidence of Death at Year 1
NCT02741323 (29) [back to overview]	Incidence of Graft Loss in Year 1
NCT02741323 (29) [back to overview]	Incidence of Non-opportunistic Infections Requiring Hospitalization Within Year 1
NCT02741323 (29) [back to overview]	Incidence of Opportunistic Infections or Neoplasms Within Year 1
NCT02741323 (29) [back to overview]	Incidence of Serious Adverse Events (SAEs) Greater Than or Equal to Grade 3 Within Year 1
NCT02741323 (29) [back to overview]	Incidence/Proportion of Antibody Mediated Rejection
NCT02741323 (29) [back to overview]	Mean CD45 Gene Expression Count (PTPRC)
NCT02741323 (29) [back to overview]	Mean CD45 Quantitative Immunohistochemistry (IHC)
NCT02741323 (29) [back to overview]	Mean eGFR at Week 52 Based on CKD-EPI Creatinine Equation
NCT02741323 (29) [back to overview]	Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52
NCT02741323 (29) [back to overview]	Plasma HIV RNA Levels (Single Copy Assay) at Week 52
NCT02741323 (29) [back to overview]	Proportion of Participants With de Novo Anti-donor Human Leukocyte Antigen (HLA) Antibodies
NCT02741323 (29) [back to overview]	Proportion of Participants With Defined CKD Stage 4 or 5 at Year 1
NCT02741323 (29) [back to overview]	Proportion of Participants With Estimated Glomerular Filtration Rate (eGFR) Less Than 60 mL/Min/1.73 m² at Week 52
NCT02741323 (29) [back to overview]	The Slope of eGFR Over Time in Year 1
NCT02778204 (13) [back to overview]	Number of Participants Failing to Meet PK Target
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Area-under-the-curve (AUC)
NCT02778204 (13) [back to overview]	Percentage of Participants Failing to Meet Long-Term Safety Endpoint Related to Maraviroc for Dose-Finding
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Area-under-the-curve (AUC)
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Average Concentration (Cavg)
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Average Concentration (Cavg)
NCT02778204 (13) [back to overview]	Number of Participants Failing to Meet PK Target
NCT02778204 (13) [back to overview]	Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding
NCT02778204 (13) [back to overview]	Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Analysis
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax)
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Time of Maximum Concentration (Tmax)
NCT02778204 (13) [back to overview]	Pharmacokinetic (PK) Parameter: Trough Concentration (Ctau)
NCT02778204 (13) [back to overview]	Percentage of Participants Failing to Meet Long-Term Safety Endpoint Related to Maraviroc for Analysis
NCT03218592 (4) [back to overview]	Hair Antiretroviral Imaging
NCT03218592 (4) [back to overview]	Plasma Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Whole Blood Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations
NCT03274804 (6) [back to overview]	Efficacy Endpoint: Disease Control Rate
NCT03274804 (6) [back to overview]	Efficacy Endpoint: Objective Response Rate
NCT03274804 (6) [back to overview]	Efficacy Endpoint: Progression-free Survival
NCT03274804 (6) [back to overview]	Feasibility Rate of a Combined Therapy
NCT03274804 (6) [back to overview]	Overall Survival
NCT03274804 (6) [back to overview]	Safety and Toxicity of a Combined Therapy Based on Subjects Who Experienced Toxicities

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,

Intervention	mg/L (Median)
	2nd Trimester	3rd Trimester	Postpartum
ETR 200mg b.i.d.	0.36	0.48	0.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.13	0.13	0.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	3.7	5.1	7.2
RAL 400mg b.i.d.	0.0621	0.064	0.0797

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	Participants (Count of Participants)
	3rd Trimester	Postpartum
EFV 600mg q.d.	20	21
MVC 150 or 300mg b.i.d.	8	7

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG	53.96	55.25
EFV 600mg q.d. With ENG	53.64	56.65

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	cells/µL (Mean)
	Baseline	Change at Week 48	Change at Week 96
Efavirenz Once Daily + CBV (DB)	935.78	-126.83	-150.27
Maraviroc Twice Daily + CBV (DB)	938.80	38.34	20.74

Intervention	participants (Number)
	Baseline: R5; Treatment failure: R5	Baseline: R5; Treatment failure: X4	Baseline: R5; Treatment failure: DM	Baseline: R5; Treatment failure: NR/NP	Baseline: DM; Treatment failure: R5	Baseline: DM; Treatment failure: X4	Baseline: DM; Treatment failure: DM	Baseline: DM; Treatment failure: NR/NP
Efavirenz Once Daily + CBV (DB)	6	0	0	4	0	0	0	0
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	5	0	3	5	0	0	5	0
Maraviroc Twice Daily + CBV (DB)	11	0	10	5	1	2	4	0

Intervention	participants (Number)
	Any Zid/Lam Mutation: Week 48 (n= 20, 43, 15)	Any TAM Mutation: Week 48 (n= 20, 43, 15)	K65R Mutation: Week 48 (n= 20, 43, 15)	M184V/I Mutation: Week 48 (n= 20, 43, 15)	Other NRTI Mutation: Week 48 (n= 20, 43, 15)	Any Zid/Lam Mutation: Week 96 (n= 27, 55, 23)	Any TAM Mutation: Week 96 (n= 27, 55, 23)	K65R Mutation: Week 96 (n= 27, 55, 23)	M184V/I Mutation: Week 96 (n= 27, 55, 23)	Other NRTI Mutation: Week 96 (n= 27, 55, 23)
Efavirenz Once Daily + CBV (DB)	3	0	0	3	0	8	2	0	8	0
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	14	1	0	14	0	20	3	0	20	0
Maraviroc Twice Daily + CBV (DB)	27	6	1	27	1	33	6	1	33	1

Intervention	Percentage of participants (Number)
	Less than 400 copies/mL	Less than 50 copies/mL
Efavirenz Once Daily + CBV (DB)	73.1	69.3
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	61.5	55.8
Maraviroc Twice Daily + CBV (DB)	70.6	65.3

Intervention	log10 copies/mL (Least Squares Mean)
	Week 48	Week 96
Efavirenz Once Daily + CBV (DB)	-2.262	-2.034
Maraviroc Twice Daily + CBV (DB)	-2.152	-1.945

Intervention	participants (Number)
	L100I Mutation: Week 48 (n= 43, 15)	K103N Mutation: Week 48 (n= 43, 15)	V106M Mutation: Week 48 (n= 43, 15)	V108I Mutation: Week 48 (n= 43, 15)	Y181C/I Mutation: Week 48 (n= 43, 15)	Y188L Mutation: Week 48 (n= 43, 15)	G190S/A Mutation: Week 48 (n= 43, 15)	P225H Mutation: Week 48 (n= 43, 15)	L100I Mutation: Week 96 (n= 55, 23)	K103N Mutation: Week 96 (n= 55, 23)	V106M Mutation: Week 96 (n= 55, 23)	V108I Mutation: Week 96 (n= 55, 23)	Y181C/I Mutation: Week 96 (n= 55, 23)	Y188L Mutation: Week 96 (n= 55, 23)	G190S/A Mutation: Week 96 (n= 55, 23)	P225H Mutation: Week 96 (n= 55, 23)
Efavirenz Once Daily + CBV (DB)	0	6	0	0	0	0	1	0	0	12	1	1	0	0	2	1
Maraviroc Twice Daily + CBV (DB)	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0

Intervention	participants (Number)
	Resistance to Zidovudine: Week 48 (n= 20, 43, 15)	Resistance to Lamivudine: Week 48 (n= 20, 43, 15)	Resistance to Efavirenz: Week 48 (n= 20, 43, 15)	Resistance to Maraviroc: Week 48 (n= 20, 43, 15)	Resistance to Zidovudine: Week 96 (n= 27, 55, 23)	Resistance to Lamivudine: Week 96 (n= 27, 55, 23)	Resistance to Efavirenz: Week 96 (n= 27, 55, 23)	Resistance to Maraviroc: Week 96 (n= 27, 55, 23)
Efavirenz Once Daily + CBV (DB)	0	3	7	NA	0	8	13	NA
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)	0	14	0	NA	0	20	0	NA
Maraviroc Twice Daily + CBV (DB)	0	27	0	12	0	33	0	NA

Intervention	cells/µL (Least Squares Mean)
	Week 24	Week 48
Maraviroc BID	111.08	122.44
Maraviroc QD	106.63	112.53
Placebo	52.14	53.97

Intervention	participants (Number)
	Change in GSS by less than -3 (n= 35 ,40, 47)	Change in GSS by -3 (n= 35 ,40, 47)	Change in GSS by -2 (n= 35 ,40, 47)	Change in GSS by -1 (n= 35 ,40, 47)	Change in GSS by 0 (n= 35 ,40, 47)	Change in GSS by 1 (n= 35 ,40, 47)	Change in GSS by 2 (n= 35 ,40, 47)	Change in GSS by 3 (n= 35 ,40, 47)	Change in GSS by greater than 3 (n= 35 ,40, 47)	Change in PSS by less than -3 (n= 35 ,40, 45)	Change in PSS by -3 (n= 35 ,40, 45)	Change in PSS by -2 (n= 35 ,40, 45)	Change in PSS by -1 (n= 35 ,40, 45)	Change in PSS by 0 (n= 35 ,40, 45)	Change in PSS by 1 (n= 35 ,40, 45)	Change in PSS by 2 (n= 35 ,40, 45)	Change in PSS by 3 (n= 35 ,40, 45)	Change in PSS by greater than 3 (n= 35 ,40, 45)
Maraviroc BID	0	0	0	13	26	1	0	0	0	0	1	1	18	17	3	0	0	0
Maraviroc QD	0	0	3	9	23	0	0	0	0	0	4	4	10	15	2	0	0	0
Placebo	1	0	1	11	32	1	0	1	0	1	1	4	12	25	2	0	0	0

Intervention	cells per microliter (cells/µL) (Mean)
	CD4	CD8
Maraviroc BID	176.5	880.1
Maraviroc QD	187.5	941.1
Placebo	178.5	880.4

Intervention	participants (Number)
	Baseline: R5, Treatment failure: R5	Baseline: R5, Treatment failure: X4	Baseline: R5, Treatment failure: DM	Baseline: R5, Treatment failure: NR/NP	Baseline: DM, Treatment failure: R5	Baseline: DM, Treatment failure: X4	Baseline: DM, Treatment failure: DM	Baseline: DM, Treatment failure: NR/NP
Maraviroc BID	15	7	22	3	0	4	5	1
Maraviroc QD	16	6	19	1	0	2	4	2
Placebo	49	0	3	3	2	1	1	0

Intervention	participants (Number)
	Change in GSS by less than -3 (n= 44 ,52, 55)	Change in GSS by -3 (n= 44 ,52, 55)	Change in GSS by -2 (n= 44 ,52, 55)	Change in GSS by -1 (n= 44 ,52, 55)	Change in GSS by 0 (n= 44 ,52, 55)	Change in GSS by 1 (n= 44 ,52, 55)	Change in GSS by 2 (n= 44 ,52, 55)	Change in GSS by 3 (n= 44 ,52, 55)	Change in GSS by greater than 3 (n= 44 ,52, 55)	Change in PSS by less than -3 (n= 44 , 52, 53)	Change in PSS by -3 (n= 44 , 52, 53)	Change in PSS by -2 (n= 44 , 52, 53)	Change in PSS by -1 (n= 44 , 52, 53)	Change in PSS by 0 (n= 44 , 52, 53)	Change in PSS by 1 (n= 44 , 52, 53)	Change in PSS by 2 (n= 44 , 52, 53)	Change in PSS by 3 (n= 44 , 52, 53)	Change in PSS by greater than 3 (n= 44 , 52, 53)
Maraviroc BID	0	0	1	17	31	2	1	0	0	1	1	3	21	23	3	0	0	0
Maraviroc QD	0	0	5	12	26	1	0	0	0	0	4	6	13	17	3	0	1	0
Placebo	1	1	2	15	33	1	1	1	0	1	3	6	12	26	4	1	0	0

Intervention	participants (Number)
	GSS: 0	GSS: 1	GSS: 2	GSS: greater than or equal to 3	GSS: missing	PSS: 0	PSS: 1	PSS: 2	PSS: greater than or equal to 3	PSS: missing
Maraviroc BID	59	80	48	47	1	24	73	69	66	3
Maraviroc QD	52	82	38	57	3	25	70	51	83	3
Placebo	31	29	21	34	3	17	18	35	45	3

maraviroc

Cross-References

Synonyms (102)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (22)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (228)

Molecular Functions (115)

Ceullar Components (47)

Bioassays (316)

Research

Studies (742)

Market Indicators

Research Demand Index: 65.61

Study Types

Clinical Trials (139)

Trial Overview

Trial Outcomes

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Plasma Concentration for Contraceptives

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96

Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48

Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96

Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96

Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population

Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels

Time to Virologic Failure

Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96

Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population

Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants

Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96

Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression

Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants

Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96

Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96

Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression

Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96

Time to Virological Failure

Change From Baseline in CD4 Cell Count at Week 24 and 48

Change From Baseline in CD8 Cell Count at Week 24 and 48

Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24

Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline

Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24

Intervention	log10copies/mL (Mean)
	Week 24; Screening OSS 0 (n= 29, 27, 19)	Week 24; Screening OSS 1 (n= 76, 86, 21)	Week 24; Screening OSS 2 (n= 51, 65, 38)	Week 24; Screening OSS >=3 (n= 68, 53, 35)	Week 24; Screening OSS= Missing (n= 4, 3, 3)	Week 48; Screening OSS 0 (n= 29, 27, 19)	Week 48; Screening OSS 1 (n= 77, 86, 20)	Week 48; Screening OSS 2 (n= 51, 64, 38)	Week 48; Screening OSS >=3 (n= 67, 54, 36)	Week 48; Screening OSS= Missing (n= 4, 3, 3)
Maraviroc BID	-1.524	-1.895	-2.220	-2.672	-3.075	-1.419	-1.868	-2.182	-2.634	-2.698
Maraviroc QD	-0.945	-1.911	-2.093	-2.536	-2.070	-0.876	-1.843	-2.146	-2.427	-2.106
Placebo	-0.083	-0.350	-1.251	-2.471	-0.530	-0.088	-0.262	-1.147	-2.205	-0.370

Intervention	participants (Number)
	Change in GSS by less than -3 (n= 35, 33, 46)	Change in GSS by -3 (n= 35, 33, 46)	Change in GSS by -2 (n= 35, 33, 46)	Change in GSS by -1 (n= 35, 33, 46)	Change in GSS by 0 (n= 35, 33, 46)	Change in GSS by 1 (n= 35, 33, 46)	Change in GSS by 2 (n= 35, 33, 46)	Change in GSS by 3 (n= 35, 33, 46)	Change in GSS by greater than 3 (n= 35, 33, 46)	Change in PSS by less than -3 (n= 35, 32, 46)	Change in PSS by -3 (n= 35, 32, 46)	Change in PSS by -2 (n= 35, 32, 46)	Change in PSS by -1 (n= 35, 32, 46)	Change in PSS by 0 (n= 35, 32, 46)	Change in PSS by 1 (n= 35, 32, 46)	Change in PSS by 2 (n= 35, 32, 46)	Change in PSS by 3 (n= 35, 32, 46)	Change in PSS by greater than 3 (n= 35, 32, 46)
Maraviroc BID	1	0	0	6	22	4	0	0	0	0	0	3	9	19	0	1	0	0
Maraviroc QD	0	0	0	12	23	0	0	0	0	0	1	3	13	16	2	0	0	0
Placebo	0	0	2	17	24	2	1	0	0	0	3	4	18	19	2	0	0	0

Intervention	participants (Number)
	Change in GSS by less than -3 (n= 22, 25, 40)	Change in GSS by -3 (n= 22, 25, 40)	Change in GSS by -2 (n= 22, 25, 40)	Change in GSS by -1 (n= 22, 25, 40)	Change in GSS by 0 (n= 22, 25, 40)	Change in GSS by 1 (n= 22, 25, 40)	Change in GSS by 2 (n= 22, 25, 40)	Change in GSS by 3 (n= 22, 25, 40)	Change in GSS by greater than 3 (n= 22, 25, 40)	Change in PSS by less than -3 (n= 22, 24, 40)	Change in PSS by -3 (n= 22, 24, 40)	Change in PSS by -2 (n= 22, 24, 40)	Change in PSS by -1 (n= 22, 24, 40)	Change in PSS by 0 (n= 22, 24, 40)	Change in PSS by 1 (n= 22, 24, 40)	Change in PSS by 2 (n= 22, 24, 40)	Change in PSS by 3 (n= 22, 24, 40)	Change in PSS by greater than 3 (n= 22, 24, 40)
Maraviroc BID	1	0	0	6	15	3	0	0	0	0	0	3	8	13	0	0	0	0
Maraviroc QD	0	0	0	9	13	0	0	0	0	0	1	2	8	10	1	0	0	0
Placebo	0	0	1	15	22	1	1	0	0	0	2	3	16	18	1	0	0	0

Intervention	cells per microliter (cells/μL) (Mean)
	CD4	CD8
Maraviroc BID	204.9	996.9
Maraviroc QD	206.0	994.6
Placebo	198.5	952.3

Intervention	log10copies/mL (Mean)
	Week 24; Screening OSS 0 (n= 22, 29, 16)	Week 24; Screening OSS 1 (n= 54, 48, 23)	Week 24; Screening OSS 2 (n= 37, 39, 21)	Week 24; Screening OSS >=3 (n= 64, 68, 29)	Week 24; Screening OSS= Missing (n= 3, 1, 2)	Week 48; Screening OSS 0 (n= 22, 29, 16)	Week 48; Screening OSS 1 (n= 54, 48, 23)	Week 48; Screening OSS 2 (n= 38, 39, 21)	Week 48; Screening OSS >=3 (n= 63, 68, 29)	Week 48; Screening OSS= Missing (n= 3, 1, 2)
Maraviroc BID	-1.231	-2.051	-2.515	-2.530	-0.544	-1.290	-1.899	-2.565	-2.426	-0.833
Maraviroc QD	-1.721	-1.822	-2.145	-2.655	-2.642	-1.745	-1.678	-2.207	-2.448	-2.795
Placebo	-0.264	-0.651	-0.611	-2.109	-1.169	-0.249	-0.594	-0.591	-1.942	-1.105

Intervention	participants (Number)
	Scr score: 0-1	Scr score: 2-4	Scr score: missing
Maraviroc BID	12	35	1
Maraviroc QD	21	35	1
Placebo	17	40	1

Intervention	days (Median)
	Week 24 (n=35, 23, 29)	Week 48 (n=45, 37, 44)
Maraviroc BID	189.00	0.00
Maraviroc QD	88.00	0.00
Placebo	100.00	0.00

Intervention	particpants (Number)
	Scr score: 0	Scr score: 1	Scr score: 2	Scr score: ≥3	Scr score: missing
Maraviroc BID	2	11	14	24	1
Maraviroc QD	1	19	21	15	1
Placebo	2	15	13	27	1

Intervention	participants (Number)
	Candidiasis	Cytomegalovirus chorioretinitis	Histoplasmosis	Oesophageal candidiasis	Pneumococcal Sepsis	Pneumocystis jiroveci pneumonia	Pneumonia	Encephalitis
Maraviroc BID	1	0	0	2	1	0	1	0
Maraviroc QD	0	1	1	0	0	3	0	0
Placebo	1	0	0	0	0	0	0	1

Intervention	participants (Number)
	Candidiasis	Cytomegalovirus chorioretinitis	Herpes simplex	Histoplasmosis	Mycobacterium avium complex infection	Oesophageal candidiasis	Pneumocystis jiroveci pneumonia	Pneumonia	Encephalitis
Maraviroc BID	0	0	0	0	0	2	1	0	0
Maraviroc QD	0	1	1	1	1	0	3	0	0
Placebo	1	0	0	0	0	0	0	1	1